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The lung was recently identified as a central site of T cell reprogramming in experimental 
autoimmune encephalomyelitis (EAE), a rodent model of multiple sclerosis (MS). While 
residing in the pulmonary tissue, central nervous system (CNS) antigen-reactive T cells become 
equipped with the potential to transgress the blood-brain barrier and induce CNS 
autoimmune disease. In order to better understand the involvement of the lung in the 
development and progression of EAE, we established an acute EAE model induced by 
intratracheal (i.tr.) immunization with the myelin antigen myelin basic protein (MBP).  
Effector-memory T cells reactive against MBP were activated within the lung tissue and 
induced severe clinical signs of EAE. The activation process was highly efficient: antigen doses 
about 100 to 1000 times lower than used for subcutaneous (s.c.) immunization were sufficient 
to trigger MBP-specific T cells to induce EAE. This effect was reproducible in animals which 
carry low numbers of neonatally transferred MBP-specific memory T cells embedded in their 
immune repertoire and lung. These observations could be of relevance in context of MS: 
Minute amounts of pathogenic epitopes resembling self-antigens in the airways of patients 
with a matching HLA haplotype expression could be sufficient to induce the activation of 
dormant autoreactive T cells in a process referred to as molecular mimicry, and consequently 
trigger disease.  
In order to identify local factors that can potentially contribute to the efficiency of the lung in 
triggering autoimmunity, we focused on the recently identified lung microbiota. Intratracheal 
administration of a locally acting antibiotic induced changes in the lung microbiota 
composition and significantly reduced EAE. The treatment did neither interfere with T cell 
activation within the lung nor change the expression profile of the transferred T cells. 
Moreover, EAE amelioration was also observed following s.c. immunization and in a transfer 
EAE model using in vitro activated T cells, suggesting that a distal rather than a local lung-
intrinsic mechanism could be causative. We observed that i.tr. antibiotic treatment induced a 
reduced MHCII expression in the CNS, potentially indicative of a functional impairment in the 
capacity of microglia or local macrophages to present antigen and consequently trigger CNS 
inflammation. 
Taken together, we observed that the lung represents a highly efficient environment for the 
activation of autoaggressive T cells and the initiation of CNS autoimmunity, and the lung 
microbiota appears to be involved in its regulation. How exactly this crosstalk between lung 
and CNS is mediated remains to be further investigated. 
1 
1. Introduction 
1.1 Multiple sclerosis (MS) 
1.1.1 Clinical picture and epidemiology of MS 
 
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). 
It is characterized by focal inflammatory demyelinating lesions resulting in axonal loss and 
neurodegeneration. The clinical manifestation is multifaceted and dependent on the CNS area 
affected. Hallmark symptoms include numbness and tingling, fatigue, mobility problems, and 
impairments of vision and cognition (Compston and Coles, 2008). 
Principally, four types of MS differing in their clinical course can be distinguished (Lublin and 
Reingold, 1996): clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary 
progressive MS (PPMS) and secondary progressive MS (SPMS). About 80 – 85 % of patients 
are initially diagnosed with RRMS, characterized by sudden relapses with subsequent episodes 
of remission. Impairments occurring during relapses either completely or only partially 
resolve, the latter accounting for 40 % of RRMS attacks with an increasing probability over 
time. RRMS usually starts with a CIS, an attack indicative of demyelination without fulfilling 
MS criteria. While in some patients a CIS remains a unique episode, between 30 and 70 % 
develop MS later in life. Around 20 years after disease onset, RRMS slowly converts into SPMS 
in around 50 – 65 % of patients. In SPMS, neurological deficits start worsening progressively 
while acute attacks and intervals of remission fade. PPMS affects 10 – 20 % of patients. 
Following initial symptoms, disability progresses steadily in absence of acute attacks and 
remission periods. The age of onset of PPMS is around 40 years, which corresponds to the 
average age of conversion from RRMS to SPMS (Fig. 1; Weinshenker et al., 1989; Lublin and 
Reingold, 1996; Miller et al., 2005; Miller and Leary, 2007; Compston and Coles, 2008). 
With around 2 – 2.5 million people affected worldwide and an age of onset between 20 and 
50 years old, MS is the most common immune-mediated disease of the central nervous 
system (CNS) and disabling neurological condition among young adults (Compston et al., 2006; 
World Health Organization, 2008). MS is particularly common among Caucasians and affects 











Figure 1: The different phases of MS. Depicted is an exemplified typical course of MS. In the pre-onset phase, the disease 
starts manifesting itself on a subclinical level. The patients are free of symptoms. Increasing immune cell infiltration and CNS 
damage at some point provoke a first attack typically lasting about 24 h and often starting with tingling or numbness of e.g. 
face or fingertips or a blurry vision. These patients are usually initially diagnosed with a clinically isolated syndrome (CIS). 
While some patients fully recover without experiencing further relapses throughout life, CIS in many patients converts to 
clinically definite MS. For several years, patients experience sudden acute attacks with subsequent remission (RRMS). Initially, 
symptomatic remission is more or less complete. Over time, however, remission starts becoming incomplete and the 
symptoms start lingering, resulting in increasing disability. Around 20 years after onset, RRMS oftentimes converts into a 
secondary-progressive course (SPMS) characterized by a progressive worsening of neurological deficits with few or no acute 
attacks or episodes of remission. Some MS patients also have a primary progressive disease course (PPMS) without acute 
attacks or episodes of remission (not depicted; adapted from Disanto et al., 2012). 
 
1.1.2 General etiology of MS 
 
The cause of MS is yet unknown. Though research has led to the identification of a number of 
treatment targets and the development of a variety of medications, MS to this day is still not 
curable and life expectancy of patients remains decreased by 5 – 10 years compared to 
unaffected individuals (Compston and Coles, 2008).  
MS is widely believed to be caused by a combination of genetic and environmental risk factors. 
According to this hypothesis, certain triggers can cause disease in individuals with a genetic 
predisposition.  
Genetic risk factors 
Indications for a genetic component are based on population-based studies that identified an 
increased risk in close relatives of MS patients which decreases with distance. The highest 
concordance rate of 25 – 30 % can be observed for monozygotic twins (Compston and Coles, 
2002; Ebers et al., 2000; Robertson et al., 1996). Genome-wide association studies (GWAS) 
could show that genetic risk factors are often immune-related. Many of the loci found to be 
associated with MS are located in the human leukocyte antigen (HLA) complex. Genes in this 
system mainly encode for major histocompatibility complex (MHC) proteins, components of 
the complement system and other factors of immunological relevance. The HLA allele 
DRB1*15:01 is often referred to as the primary MS risk variant. GWAS found that single 
nucleotide polymorphisms in this gene show a strong association with MS. Other loci 
described to be associated with an increased MS risk include genes encoding for cytokine 
receptors (IL-2RA, IL-7RA) and costimulatory molecules (B7-1, B7-2), indicating that genetic 
predisposition commonly goes hand in hand with an immunological dysfunction (Baranzini, 
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2011; Compston and Coles, 2008; International Multiple Sclerosis Genetics Consortium et al., 
2011).  
Environmental risk factors 
Besides genetics, a variety of environmental risk factors has been described to be associated 
with MS, including childhood obesity, reduced vitamin D levels as a result of insufficient 
sunlight exposure in the Northern Hemisphere, a dysregulation of the gut microbiome, 
smoking, and viral infections (Ascherio, 2013; Ascherio and Munger, 2007a, 2007b; Ascherio 
et al., 2010; Compston and Coles, 2008). 
 
1.1.3 Lung-associated MS risk factors 
 
Due to the relatively large surface of the pulmonary epithelium and the correspondingly 
intense contact with the environment, the lung is particularly vulnerable. In addition, the lung 
is equipped with a highly specialized immune system, which aims to control the colonization 
by pulmonary pathogens. Given these characteristics, it is not surprising that disturbances of 
this delicate and complex system have been described to affect MS susceptibility, indicating 
an involvement of the lung in its pathogenesis. 
As indicated above, many of the environmental factors observed to be correlated with an 
increased MS risk are lung-associated. In fact, a variety of inflammatory conditions of the 
upper respiratory system have been implicated in MS manifestation (Panitch, 1994; Correale 
et al., 2006). In particular, infections with viruses such as influenza or herpesviruses like 
Epstein-Barr (EBV) or Cytomegalovirus (CMV) are believed to increase the risk of developing 
MS and exacerbate its course (Halenius and Hengel, 2014; Lang et al., 2002; Oikonen et al., 
2011). Indeed, viral infections of the lung appear to be strongly correlated with an increased 
relapse rate (Sibley et al., 1985; Buljevac et al., 2002). 
Furthermore, cigarette smoking was found to be strongly associated with both an increased 
disease susceptibility and a more rapid disease progression (Antonovsky et al., 1965; 
Ghadirian et al., 2001; Hernán et al., 2001; Riise et al., 2003; Pekmezovic et al., 2006; Ascherio 
and Munger, 2007b; Hedström et al., 2009, 2013; Jafari and Hintzen, 2011). Compared to 
nonsmokers, smokers have an approximately 1.2 to 1.8-fold increased relative risk to develop 
MS (Riise et al., 2003; Hawkes, 2007). Additionally, MS patients that started smoking early in 
life tend to develop a chronic clinical course more frequently and after a shorter disease 
duration, and their risk of disability progression is significantly increased (Sundström and 
Nyström, 2008). Similar to smoking, the often consequential chronic obstructive pulmonary 
disease (COPD) has been shown to correlate with an increased MS-risk (Egesten et al., 2008). 







1.1.4 Pathogenesis of MS 
 
A clear mechanistic basis of the pathogenesis underlying MS remains to be unraveled. 
However, multiple lines of evidence suggest that auto-aggressive CNS-reactive effector T 
lymphocytes are the culprits of MS (Compston and Coles, 2002, 2008; Kebir et al., 2007; Shi et 
al., 2007; Tzartos et al., 2008; Viglietta et al., 2004). Autoantigen-specific T cells can be found 
in the immune repertoire of healthy individuals. Usually, these cells are quiescent and 
harmless for the organism. In contrast, in the context of MS, it is thought that these cells 
become activated in the periphery and consequently are somehow able to cross the blood-
brain barrier (BBB), a structure that in healthy individuals strongly limits immune cell 
infiltration into the CNS. Once infiltrated, the T cells cause tissue-damaging inflammatory 
responses and MS-typical lesions. The hypothesis that T cells are the major disease-driving 
factor of MS is strongly supported by the fact that most of the available MS drugs directly or 
indirectly affect the differentiation, migration or activation of T cells (Baecher-Allan et al., 
2018):  
Natalizumab for instance is a monoclonal antibody directed against very late antigen-4 (VLA-
4). Interference with VLA-4 prevents activated T cells from adhering to and transgressing 
through the BBB. Another MS drug targeting T cells is Fingolimod. Treatment with this 
immunomodulatory drug induces the internalization of sphingosine-1-phosphate (S1P) 
receptors, thereby preventing potentially autoreactive T cells from exiting the lymph nodes 
and entering the CNS. Glatiramer acetate (GA) is another immunomodulatory medication 
commonly used to treat MS. GA is a random copolymer composed of four amino acids also 
found in myelin basic protein (MBP). It can bind to MHC class II molecules including HLA-DR2, 
thereby inhibiting the activation of MBP-specific autoreactive T cells (O’Brien et al., 2010). 
Despite strong indications that T cells play a key role for the initiation and progression of MS, 
it remains to be clarified where, when and how auto-reactive T cells are activated and 
equipped with the potential to overcome the BBB and infiltrate the CNS. 
 
1.2 Experimental autoimmune encephalomyelitis (EAE) 
 
Today´s understanding of MS pathogenesis is to a high degree based on studies in the main 
MS animal model, experimental immune encephalomyelitis (EAE). In this model, myelin-
reactive CD4+ T cells are the definite cellular cause of disease. The history of EAE can be traced 
back to the early 1930s, when Thomas Milton Rivers immunized Rhesus monkeys with rabbit 
CNS homogenate and subsequently observed the formation of perivascular demyelinating 
lesions reminiscent of MS pathophysiology (Rivers et al., 1933). Thereby, he could show that 
a peripheral immune response can cause CNS autoimmunity. Ever since, EAE has steadily been 
refined and induced in a variety of animals including guinea pigs, rabbits and non-human 
primates. Today, EAE is well-established and most commonly used in rodents like mice and 
rats (Mannie et al., 2009; Miller et al., 2010). In most of the cases, EAE in these animals is 
clinically characterized by an ascending paresis starting with weight loss and a reduced tail 
tonus and developing into complete paralysis of tail and hind limbs at the peak of disease.  
5 
EAE can be induced in two ways; actively by immunization with myelin antigens or passively 
by transfer of myelin-reactive CD4+ T cells.  
 
1.2.1 Active EAE (aEAE) 
 
To induce active EAE (aEAE), animals are immunized with myelin antigens such as myelin basic 
protein (MBP), myelin oligodendrocyte glycoprotein (MOG) or proteolipid protein (PLP) mixed 
with an adjuvant (Fig. 2; Lipton and Freund, 1953; Mannie et al., 2009; Miller et al., 2010). 
Upon encounter with their cognate antigen presented by professional antigen-presenting cells 
(APCs), potentially autoreactive naïve T cells are primed and differentiate into effector T cells 
in lymph nodes draining the site of immunization. After several rounds of expansion, the cells 
exit the lymph nodes, enter the circulation and manage to overcome the BBB. In the CNS, they 
are reactivated by local APCs presenting their cognate antigen. Upon reactivation, T cells 
release proinflammatory cytokines and chemokines which leads to a massive recruitment of 
immune cells including lymphocytes and monocytes / macrophages, thereby triggering a 
cascade of inflammation, demyelination and local damage causing the clinical symptoms 
described above (Mix et al., 2010). 
 
 
Figure 2: Potential primary target antigens in multiple sclerosis. T cells reactive against myelin-associated glycoprotein 
(MAG), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP) are frequently 
identified in the immune repertoire of MS patients. MBP, MOG and PLP are commonly used as encephalitogenic antigens to 
induce EAE in different rodent models. (Adapted from Hemmer et al., 2002). 
 
1.2.2 Passive transfer EAE (ptEAE) 
 
In the passive transfer EAE (ptEAE) model, myelin-reactive CD4+ T cells are isolated from the 
draining lymph nodes of actively-immunized animals before EAE onset. After in vitro 
activation, the cells are transferred into naïve recipient animals. After an asymptomatic period 
of 3 – 4 days, the cells invade the CNS, causing neurological disease as described above for 
aEAE (Fig. 3). The fact that T cell transfer alone is sufficient to induce CNS autoimmunity 
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proved their crucial role as culprits in EAE and potentially in MS (Paterson, 1960; Ben‐Nun et 
al., 1981). The ptEAE model has a key advantage: CNS-reactive CD4+ T cells isolated from 
immunized animals can be retrovirally transduced to express fluorescent markers, allowing to 
track and functionally characterize the cells at any point on their route into the CNS of 
recipient animals (Flügel et al., 1999). 
 
Figure 3: Generation and passive transfer of autoreactive T cells. Rats are subcutaneously immunized with myelin basic 
protein (MBP) emulsified in Complete Freund´s Adjuvant (CFA). Nine days post-immunization, draining lymph nodes are 
isolated and brought to single cell suspension. The lymph node cells including MBP-reactive T (TMBP) cells are co-cultured with 
GP+E86 (GPE) packaging cells. Thereby, the T cells are retrovirally transduced to express GFP. The T cells are stimulated with 
MBP, resulting in their activation. Adding IL-2 on D2 post-stimulation leads to proliferation and expansion of the cells, before 
they again become resting around 6 days post-stimulation. On D7 post-stimulation, the cells can again be re-stimulated. This 
cycle of T cell stimulation and expansion can usually be repeated 5 – 6 times. On D2 post-stimulation, the fully activated TMBP-
blast cells can be adoptively transferred into naïve recipient animals, resulting in the induction of EAE after 3 – 4 days. 
 
1.2.3 The lung as a critical site of T cell reprogramming in EAE 
 
Using the ptEAE model in the Lewis rat (Paterson, 1960; Ben‐Nun et al., 1981; Flügel et al., 
1999), it could be observed that fluorescently-labelled MBP-reactive T cells previously 
activated in vitro (TMBP-blast cells) vanished from the circulation of recipient animals within 
minutes following intravenous (i.v.) transfer. Neither could they be found in the blood, nor did 
they home to secondary lymphoid organs like lymph nodes or spleen. Only around 48 hours 
post-transfer (p.t.), the cells started reappearing in blood and spleen, just before entering the 
CNS. When examining the transferred cells´ location during the prodromal phase, Odoardi and 
colleagues (2012) observed the cells to home to the lung shortly upon transfer. Within the 
first 12 h, they mainly resided in the peripheral lung tissue. About 24 – 48 h p.t., the cells 
migrated along bronchial structures and accumulated in bronchus-associated lymphoid 
tissues (BALT). About 48 h p.t., just before their reappearance in blood and spleen, they were 
found in high numbers in the lung-draining mediastinal lymph nodes (Odoardi et al., 2012).  
Strikingly, while residing in the lung, their gene-expression profile was fundamentally 
reprogrammed: while transcription of genes involved in T cell activation and proliferation was 
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decreased, expression of genes relevant for T cell motility, cell adhesion and migration was 
highly increased (Fig. 4; Odoardi et al., 2012). 
In addition, the transferred TMBP-blast cells changed their responsiveness to migration stimuli, 
explaining their reorientation within the lung tissue. Initially, the freshly immigrated T cells 
responded to homeostatic chemokines (CCL19 and -21), which are mainly expressed in the 
respiratory tract and BALT. On their way, the T cells upregulated S1PR1, a sphingolipid-
responsive receptor that controlled the egress of cells from the lung. Furthermore, 
inflammatory chemokine receptors (CCR5 and CXCR3) were upregulated, facilitating T cell 
attachment to the CNS endothelium (Odoardi et al., 2012). Thus, while residing in the lung, 
the transcription profile of transferred TMBP-blast cells was switched from an activatory to a 
migratory state (TMBP-migratory cells).  
 
Figure 4: The route of autoreactive T cells from injection to CNS infiltration. Within minutes following adoptive transfer, 
TMBP-blast cells started homing to the lung. While residing within the pulmonary environment, the cells switched their gene 
expression profile from an activatory to a migratory state. Around two days post-transfer, the cells started migrating into the 
lung-draining mediastinal lymph nodes (not depicted) before reappearing in blood circulation and spleen around D3 after 
transfer, just before CNS infiltration. The residence and reprogramming in the lung were prerequisite for the cells to 
transgress the BBB and enter the CNS (adapted from Ransohoff, 2012). 
This profound reprogramming in the lung was found to be substantial for the ability of the T 
cells to enter the CNS, which could further be confirmed in an anastomotic experimental 
setup: 48 h after TMBP-blast cell transfer, the blood circulations of the recipient and a naïve rat 
were conjoined. The transferred cells at that point had already been reprogrammed in the 
recipient animal´s lung. The TMBP-migratory cells passing through the shunt within 12 h of 
anastomosis started infiltrating the conjoined naïve rat´s CNS in similar frequencies and at the 
same time as in the recipient rat, thereby excluding a CNS preconditioning. Moreover, TMBP-
migratory cells isolated from spleens of TMBP-blast cell recipients 60 h post-transfer readily migrated 
to and infiltrated the CNS of naïve animals shortly after re-transfer (Odoardi et al., 2012).  
The stimulatory potential of the lung could further be demonstrated when intratracheally 
(i.tr.) immunizing so-called memory animals with MBP. To generate these memory animals, 
rats are neonatally transferred with memory TMBP cells. When injected until postnatal D2 – 3, 
these cells are tolerated by and embedded into the recipient animals´ immune system. They 
persist lifelong in low numbers in lymph nodes, spleen, and notably also in the lung (Kawakami 
et al., 2005). Upon i.tr. immunization of the adult memory animals, the memory TMBP cells 
became activated and strongly proliferated in lung and mediastinal lymph nodes. 
Subsequently, the cells egressed the lung environment and entered the blood stream before 
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infiltrating the CNS and triggering EAE (Odoardi et al., 2012). Taken together, these findings 
clearly demonstrate the relevance of the lung as a critical site of stimulation and acquisition 
of pathogenicity of auto-reactive T cells in a model of CNS autoimmunity, suggesting a 
potentially similar role of the lung in the context of MS.  
 
1.3 Potential mechanistic links between lung and CNS autoimmunity 
 
Until recently, the lung had not been considered to be of immunological relevance for the 
trafficking of autoaggressive T cells to the CNS. The identification of the lung as the central 
checkpoint of T cell reprogramming in its animal model EAE was surprising (Odoardi et al., 
2012). The observation that in EAE a transient residence in the pulmonary environment 
appears to be a prerequisite for CNS-reactive T cells to infiltrate the CNS now raises the 
question of whether and how the lung might be of similar relevance in the context of MS.  
As mentioned earlier, many of the environmental factors described to be associated with MS 
suggest an implication of the lung in its pathogenesis. Most studies correlating inflammatory 
lung conditions with an increased MS risk are of descriptive nature and lack a mechanistic 
basis. Potential mechanisms include a bystander activation of normally quiescent CNS-
reactive T cells under chronic inflammatory conditions. Moreover, in the context of lung 
infections, viral or bacterial epitopes presented to T cells by professional APCs could share an 
identical or similar peptide sequence with certain CNS proteins. Potentially CNS-reactive T 
cells activated when encountering the pathogenic antigen in the lung could falsely be 
activated and trigger an autoimmune response against akin self-antigens in the CNS, a concept 
referred to as molecular mimicry (Lang et al., 2002; Wucherpfennig and Strominger, 1995).  
In line with chronic obstructive conditions or infections of the lung, a potentially consequential 
dysregulation of the local microbiome may contribute to an altered MS susceptibility. 
Indications stem from studies focused on the gut microbiota. Given its significant contribution 
to the development and maintenance of the immune system, the composition of the microbial 
intestinal flora has recently been extensively discussed as an important component in the 
development of autoimmune diseases (Jangi et al., 2016; Ochoa-Repáraz et al., 2009). Its 
importance could already be demonstrated in the MS animal model EAE. For instance, the oral 
treatment of mice with a broad-spectrum of antibiotics, resulting in a reduction of the gut 
microbiota, could significantly ameliorate the development of EAE in two different mouse 
strains, SJL and C57BL/6 (Ochoa-Repáraz et al., 2009). The authors observed the protective 
effect to be associated with a reduced expression of pro-inflammatory and an increased 
expression of anti-inflammatory cytokines and suggested a role of regulatory T cells for the 
maintenance of peripheral immune homeostasis (Ochoa-Repáraz et al., 2009). 
In line with this observed effect, raising mice in sterile conditions could be shown to 
completely prevent disease in a spontaneous relapsing-remitting SJL mouse model of EAE 
(Berer et al., 2011; Goverman et al., 1993). In these transgenic mice, the majority of CD4+ T 
cells expresses a transgenic T cell antigen receptor (TCR) specific for MOG peptide 92 – 106. 
When rearing the mice under specific pathogen-free conditions, about 80 % of these animals 
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spontaneously developed EAE within 3 to 8 months. Rearing these mice in germ-free 
conditions, however, completely protected the animals from developing EAE. Moreover, mice 
kept in germ-free conditions for 6 – 12 weeks promptly developed EAE upon recolonization 
with conventional microbiota, indicating that germ-free rearing per se did not induce a general 
immune deficiency and that in deed the absence of a commensal microbiota protected the 
mice from developing disease (Berer et al., 2011). Along with more and more emerging lines 
of evidence, these findings indicate a crucial role of the gut microbiota in the regulation of MS 
development (Chu et al., 2018; Joscelyn and Kasper, 2014). Gut microbiota dysbiosis is 
suggested to increase MS risk and was already found to be associated with the systemic 
autoimmune disease rheumatoid arthritis (Budhram et al., 2017; Zhang et al., 2015), as well 
as neurodegenerative disease like Alzheimer´s disease and Parkinson´s disease (Parashar and 
Udayabanu, 2017; Westfall et al., 2017). 
For a long time, the lung was thought to be sterile under physiological conditions. Owing to 
ongoing advancements in the development of molecular techniques for the investigation of 
bacterial communities, however, it could recently be shown that the lung is indeed colonized 
by a complex microbial flora. Like in the gut, the predominant phyla colonizing the healthy 
lung are the Gram-negative Bacteriodetes and Gram-positive Firmicutes. Prominent genera 
abundant in the healthy lung are Prevotella, Veillonella, Streptococcus and Pseudomonas 
(Dickson et al., 2013, 2014). Despite some similarities, the microbiota composition of gut and 
lung in general differ significantly (Dickson and Huffnagle, 2015). This can easily be attributed 
to the very distinct physiological characteristics of both environments: the gastrointestinal 
tract harbors a variety of different compartments as well as physical and chemical barriers. 
The stomach for instance is acidic with a pH of around 2 whereas the duodenum is alkaline 
with a pH of around 8. Consequently, the microbiota composition varies between the different 
gastrointestinal compartments but is generally stable. Due to the lack of a real physical barrier 
between lung and the environment, the microbiota of the lung is more dynamic and transient 
compared to the gut. Another obvious difference between gut and lung is the bacterial 
density: microbiota colonizing the gut outnumber those found in the lung by orders of 
magnitude (Dickson and Huffnagle, 2015; Scales et al., 2016; Dang and Marsland, 2019). 
While research focused on the role of the gut and its microflora in regulating autoimmune 
diseases has already entered the focus of researchers worldwide, little in this context is yet 
known about the lung and its microbiota. Dysbiosis of the lung microbiota has been described 
in a variety of patients with inflammatory and obstructive conditions of the lung including the 
MS risk factors COPD and cigarette smoking (Charlson et al., 2010; Hilty et al., 2010). Given 
that growing evidence points toward an implication of the lung as a key player in the 
pathogenesis of MS, understanding how the local microflora could be linked to MS 





1.4 Aims and objectives 
 
Aim of my project was to better understand the role of the lung in shaping CNS autoimmunity. 
Especially, we wanted to examine its function as a potentially critical site of CNS-reactive T cell 
activation and EAE initiation. Moreover, we wanted to examine how antibiotic treatment of 
the commensal lung microbiota may affect clinical aspects of EAE. 
 
1.4.1 Establishment and characterization of an i.tr. induced EAE model 
 
In order to examine efficiency and relevance of the lung for T cell activation, we aimed to 
establish a model based on intrapulmonary activation of MBP-specific T effector memory 
(TMBP-EM) cells by i.tr. immunization. To this end, we first determined the optimal combination 
of antigen and adjuvant to efficiently induce EAE. Subsequently, we performed an in-depth 
characterization of the model by determining TMBP cell distribution and activation state in 
various organs at critical time points post-immunization.  
 
1.4.2 Effect of intrapulmonary antibiotic treatment on EAE 
 
Using the established i.tr. induced EAE model, we wanted to test whether an alteration of the 
lung microbiota composition via local antibiotic treatment might affect EAE in a similar way as 
described for the gut. To this end, rats were intratracheally treated daily with different doses 
of Neomycin, a non-absorbable aminoglycoside, for 7 days. Subsequently, inflammation state 
and microbiota composition of the lung were determined. Moreover, EAE was induced via the 
lung and the clinical course monitored. After observing that local antibiotic treatment could 
indeed prevent EAE, the Neomycin dose efficiently blocking disease without causing lung 














2. Materials and Methods 
2.1 Materials 
2.1.1 Media and buffers  
 
All buffers were prepared with water purified using a Milli-Q purification system (Merck, 
Germany) unless otherwise indicated. 
 
Dulbecco´s Modified    13.4 g / L DMEM Powder 
Eagle Medium (DMEM)      (Thermo Fisher Scientific, USA) 
      3.72 g / L NaHCO3 
(Roth, Germany) 
 
Eagle´s HEPES medium (EH)   75 %  DMEM 
      25 %  HEPES 1M  
(Thermo Fisher Scientific, USA) 
 
Phosphate-buffered saline (10x PBS) 8.1 mM Na2HPO4 (Roth, Germany) 
      1.47 mM Na2H2PO4 (Roth, Germany) 
      137 mM NaCl (Roth, Germany) 
      2.68 mM  KCl (Roth, Germany) 
       adjusted to pH 7.2 – 7.4 with HCl  
(Roth, Germany) 
 
Tris-acetate-EDTA buffer (50x TAE)  242 g  Tris Free base 
(Thermo Fisher Scientific, USA) 
      18.61 g Na2xEDTA (Roth, Germany) 
      57.1 mL Glacial Acetic Acid   
        (Merck, Germany) 
        ad 1 L 
 
T cell medium (TCM)    950 mL DMEM 
      10 mL  Non-essential amino acids  
(Thermo Fisher Scientific, USA) 
      10 mL  Penicillin / Streptomycin 
        (Thermo Fisher Scientific, USA) 
      10 mL  Sodium pyruvate 
        (Thermo Fisher Scientific, USA) 
      10 mL  L-asparagine monohydrate  
        (Sigma Aldrich, Germany) 
      10 mL  L-glutamine 
        (PAN Biotech, Germany) 
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      4 µL  -mercaptoethanol (13.6 mol / L) 
        (Thermo Fisher Scientific, USA) 
  
Re-stimulation medium (RM)  99 %  TCM 
      1 %  Rat serum (In-house production) 
 
T cell growth factor medium (TCGF)  85 %  TCM 
      10 %  Horse serum (Merck, Germany) 
      5 %  Conditioned medium from 
Concanavalin A-treated 
splenocytes (Con A supernatant; 
Rosenberg et al., 1978) 
 
FACS buffer     2 mM  Na2xEDTA (Roth, Germany) 
      0.5 %  Albumin Fraction V   
        (Roth, Germany) 
        in 1x PBS 
 
Freezing medium (FM)   80 %  Horse serum (Merck, Germany) 
      10 %  TCM 
      10 %  DMSO (Roth, Germany) 
 
Thawing medium (TM)   90 %  EH 
      10 %  Fetal calf serum (Merck, Germany) 
 
Ammonium-chloride-potassium buffer 0.15 mol / L NH4Cl (Roth, Germany) 
(ACK)      1 mmol / L KHCO3 (Roth, Germany) 
      0.1 mmol / L Na2xEDTA (Roth, Germany) 
       Adjusted to pH 7.2 – 7.4 with HCl  
(Roth, Germany) 
 
APC isolation buffer    500 mL 1x DPBS without CaCl2 and MgCl2 
        (Thermo Fisher Scientific, USA) 
      0.5 %  Albumin Fraction V   
        (Roth, Germany) 
 
Digestion buffer    15 mL  EH 
      0.4 u / mL Liberase (Roche, Switzerland) 
      120 u / mL DNase I (Roche, Switzerland) 
 
14.5 % Nycodenz solution   1.45g  Nycodenz (Axis-Shield, UK) 
      9.5 mL  1x PBS 
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Isotonic Percoll (Isopercoll)   90 %  Percoll (GE Healthcare, USA) 
      10 %  10x PBS 
 
Underlay Percoll    64.22 % Isopercoll 
      35.78 % 1x PBS 
  
40 % Percoll     40 %  Isopercoll 
      60 %  1x PBS 
 
70 % Percoll     70 %  Isopercoll 
      30 %  1x PBS 
 
2.1.2 Reagents, chemicals and sera 
 
Anti-PE MicroBeads    Miltenyi Biotec, Germany 
Albumin Fraction V     Roth, Germany 
APC beads (BD Calibrite)   BD Biosciences, USA    
-Mercaptoethanol     Roth, Germany 
B. thuringiensis BTI18246 DNA   In-house production 
Chloroform     Roth, Germany 
Diethylether     Roth, Germany 
Dimethyl sulfoxide (DMSO)   Roth, Germany 
DMEM powder    Thermo Fisher Scientific, USA 
DNase      Roche, Switzerland 
DPBS (10x) without CaCl2 and MgCl2  Thermo Fisher Scientific, USA 
Ethidium bromide    Merck, Germany 
Fetal calf serum (FCS)    Merck, Germany 
GeneRuler 1 kb DNA ladder    Thermo Fisher Scientific, USA 
Glycogen     Roche, Switzerland 
G-418 sulfate solution   Capricorn Scientific, Germany 
HEPES      Thermo Fisher Scientific, USA 
Horse serum     Merck, Germany 
Hydrochloric acid (HCl)   Roth, Germany 
Incomplete Freund´s Adjuvant (IFA)  BD Biosciences, USA  
Isopropanol     Roth, Germany 
Isotonic saline solution (NaCl, 0.9 %) B. Braun, Germany  
Liberase     Roche, Switzerland 
Low-electroendosmosis (LE)-Agarose  Biozym, Germany 
Lymphocyte separation medium 1077 PromoCell, Germany  
(LSM1077) 
Lysozyme from chicken egg   Serva, Germany 
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M. tuberculosis H37Ra   BD Biosciences, USA 
Neomycin     Thermo Fisher Scientific, USA 
Nycodenz     Axis-Shield, UK 
Orange DNA Loading Dye (6x)  Thermo Fisher Scientific, USA 
Paraformaldehyde (PFA)   Roth, Germany 
TRI Reagent     Merck, Germany 
Trypsin-EDTA solution (10x)   Merck, Germany     
qPCR Mastermix    Eurogentec, Belgium 
 
2.1.3 Antigens and adjuvants 
  
Myelin basic protein (MBP)   In-house production   
isolated from guinea pig brains  
 
Ovalbumin (OVA) from chicken egg white Merck, Germany 
     
Complete Freund´s Adjuvant (CFA, stock) 40 mg M. tuberculosis H37Ra 
      (BD Biosciences, USA) 
      10 mL Incomplete Freund´s Adjuvant (IFA)  
      (BD Biosciences, USA) 
2.1.4 Antibodies 
 
Table 1: List of antibodies used for cell staining 
Antibody Fluorochrome Clone Dilution Brand 
Mouse IgG1anti-rat CD8a PE OX-8 1:200 BioLegend, USA 
Mouse IgG1 anti-rat RT1B FITC OX-6 1:200 BD Biosciences, USA 
Mouse IgG1 anti-rat TCR  AF647 R73 1:200 BioLegend, USA 
Mouse IgG2a anti-rat CD11b/c PE OX-42 1:200 BioLegend, USA 
Mouse IgG2a anti-rat CD11b/c  AF647 OX-42 1:200 BioLegend, USA 
Mouse IgG1 anti-rat CD45RA PE OX-22 1:200 BioLegend, USA 
Mouse IgG1 anti-rat CD31 PE TLD-3A12 1:100 BD Biosciences, USA 
Mouse IgG1 anti-rat CD4 PE/Cy7 W3/25 1:200 BioLegend, USA 
Mouse IgG2a anti-rat CD172a PE OX-41 1:100 BioLegend, USA 
Mouse IgG1 anti-rat CD45 AF647 OX-1 1:100 BioLegend, USA 
Mouse IgM anti-rat RP3  - - 1:50 In-house production 
Rat IgG2a anti-mouse IgM  PE R6-60.2 1:200 BD Biosciences, USA 
Mouse IgG1 anti-rat CD25 - OX-39 1:150 Bio-Rad, USA 
Mouse IgG1 Isotype control - - 1:150 Bio-Rad, USA 
Mouse IgG1 anti-rat TCR V8.2/8.4 - R78 1:100 BioLegend, USA 
Mouse IgG1 anti-rat TCR V8.5 - B73 1:100 Bio-Rad, USA 
Mouse IgG2a anti-rat TCR V10 - G101 1:100 Bio-Rad, USA 
Mouse IgG2b anti-rat TCR V16 - HIS42 1:100 OriGene, USA 




Phusion High-Fidelity DNA Polymerase Kit Thermo Fisher Scientific, USA 
RevertAid First Strand cDNA Synthesis Kit Thermo Fisher Scientific, USA 
MagSi-NGS Plus Kit     MagnaMedics, Netherlands 
MiSeq Reagent Kit v3    Illumina, USA 
QIAamp cador Pathogen Mini Kit   QIAGEN, Netherlands 
QIAamp Fast DNA Stool Mini Kit   QIAGEN, Netherlands 
Rat CD4+ T cell Isolation Kit   Stemcell Technologies, Canada 
 
2.1.6 Equipment and consumables 
2.1.6.1 Equipment 
 
Cryobox     Nalgene, USA 
Metal cell strainer (40 µm)   UMG technical workshop, Germany 
MidiMACS Separator    Miltenyi, Germany 
Multichannel pipette    StarLab, Gemany 
Pipettes (2.5; 10; 20; 100; 200; 1000 µL) Eppendorf, Gemany 
Pipetus     Hirschmann, Gemany 
Small Animal Laryngoscope LS-2   Penn Century, USA 
Tuberculin glass syringes    Poulten & Graf, Germany 




Cell strainers (40 µm, 70 µm)  Greiner Bio-One, Austria / Germany  
Winged catheter (18G)   B. Braun, Germany 
Reaction tubes (0.2, 1.5, 2 mL)  Sarstedt, Germany 
Conical centrifuge tubes (15, 50 mL)  Greiner Bio-One, Austria / Germany  
Pipette tips (10, 100, 200, 1000 µL)  StarLab, Germany 
Pipette filter tips (10, 100, 200, 1000 µL) StarLab, Germany 
Parafilm     Pichiney Plastic Packaging, USA 
Cell culture plates (12-, 24-, 96-well) Thermo Fisher Scientific, USA 
qPCR plates     StarLab, Germany 
Petri dishes (5, 10 mL)   Greiner Bio-One, Germany 
Surgical suture    B. Braun, Germany 
Syringes (5, 10 mL)    B. Braun, Germany 
Cannulas (18G, 20G, 24G, 26G)  B. Braun, Germany 
FACS tubes     BD Biosciences, USA 
MACS LD Columns    Miltenyi, Germany 
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2.1.7 Instruments and machines 
 
Axiovert 200M fluorescence microscope Zeiss, Germany 
Axiovert 40C binocular microscope  Zeiss, Germany 
Centrifuge 5415 R    Eppendorf, Gemany  
CytoFLEX S     Beckman Coulter, USA 
EV231 power supply    Consort, Belgium 
FACSAria II     BD Biosciences, USA  
FACSCalibur     BD Biosciences, USA 
ImageQuant 100 image capture system  GE Healthcare, USA 
Amersham Biosciences, UK 
Heracell 240 incubator    Heraeus, Germany 
Laminar flow hood     Heraeus, Germany 
Mastercycler Nexus Gradient  Eppendorf, Germany 
Multifuge 1 S-R    Heraeus, Germany 
NanoDrop-ND1000     Thermo Fisher Scientific, US 
StepOnePlus Real-Time PCR System  Applied Biosciences, USA 
 
2.1.8 Software and plug-ins  
 
Ampvis2     Andersen et al., 2018 
BLAST+ (Version 2.7.1)   NCBI, USA 
CellQuest Pro (Version c0.0)   BD Biosciences, USA 
cutadapt (Version 1.18)   Martin, 2011 
FACSDiva Software (Version 8.0.1)  BD Biosciences, USA 
fastp (Version 0.19.4)    Chen et al., 2018 
FlowJo (Version 10)    FlowJo LCC, USA 
ggplot2     Wickham, 2016 
GraphPad Prism (Versions 6 – 8)  GraphPad, USA 
Microsoft Office (2010, 2016)  Microsoft, USA 
MiSeq marker gene pipeline (Version 1.7) Dominik Schneider 
PEAR (Version 0.9.11)   Zhang et al., 2014 
RStudio (Version 1.1.463)   RStudio, USA 
StepOnePlus Software (Version 2.0)  Applied Biosciences, USA 
VSEARCH (Version 2.9.1)   Rognes et al., 2016 
DAVID (Version 6.8)    LHRI, USA 






6 – 8 weeks old wild type and TCRMBP-transgenic Lewis rats (Kitz, 2013) on a LEW/Crl (Rattus 
norvegicus) background were used for all experiments as well as the generation of T cell lines. 
The animals were kept in GR9000 IVC cages at a 12/12 h light/dark cycle with food and water 
provided ad libitum. The animals were bred and raised at the animal facilities of the University 
Medical Center Göttingen (UMG) in Göttingen and Holtensen. All experiments were 
performed in accordance with the local regulations of animal welfare of Lower Saxony, 
Germany. 
 
2.2.2 Generation and culture of primary T cell lines 
 
MBP- or OVA-reactive T cells retrovirally transduced to express eGFP (GFP) or mCherry 
(Cherry) were generated as reported previously (Flügel et al., 1999). 6- to 8-week-old female 
Lewis rats were briefly anesthetized with diethyl ether and immunized with an emulsion 
consisting to equal parts of guinea pig MBP or OVA (1 mg / mL) and CFA (2 mg / mL). The 
emulsion was prepared using tuberculin glass syringes (Poulten & Graf, Germany) and injected 
subcutaneously at the tail base (50 µL each side) and into the popliteal cavity (25 µL each side). 
9 – 10 days p.i., the animals were asphyxiated with CO2. The draining lymph nodes (inguinal, 
paraaortic, popliteal) were isolated and brought to single cell suspension using a 40 µm cell 
strainer. The cells were washed with EH and centrifuged at 1200 rpm and 4 °C for 6 min. 
Afterwards, the pellet was resuspended in RM and brought to a concentration of 4 x 106 lymph 
node cells / mL. The cells were subsequently co-cultured with GP+E86 packaging cells 
producing replication-deficient GFP or Cherry retroviruses carrying a G-418-resistance 
cassette and thereby transduced to express either fluorescent protein. To this end, the 
GP+E86 cells had previously been thawed and propagated in petri dishes in TCM containing 
10 % FCS and G-418 (Capricorn Scientific, Germany 0.4 mg / mL) at 5 % CO2 and 37 °C (Heracell 
240, Heraeus, Germany) for 7 days. When reaching confluency 3 – 4 days prior to starting the 
T cell culture, the GP+E86 cells were trypsinated with 1x Trypsin-EDTA (Merck, Germany), 
diluted 1 : 8 – 10 with TCM containing 10 % FCS, replated and incubated as described. 4 – 6 h 
prior to the lymph node cell isolation, the GP+E86 cells were again trypsinated, washed with 
EH and centrifuged at 1200 rpm and 4 °C for 6 min. The GP+E86 cell were resuspended in RM 
at a concentration of 3 x 105 / mL. 50 µL of the GP+E86 cell suspension were equally distributed 
to the wells of U-bottom 96-well plates. The plates were incubated at 10 % CO2 and 37 °C 
(Heracell 240, Heraeus, Germany) until 50 µL of the lymph node cell suspension were added 
to each well, resulting in 2 x 105 lymph node cells and 1.5 x 104 GP+E86 cells in a final volume 
of 100 µL per well. In addition and dependent on the antigen used for immunization, MBP or 
OVA was added at a concentration of 7 µg / mL final volume. Incubation at 10 % CO2 and 37 
°C was continued. 2 days later, 50 µL TCGF were added to each well. Another 2 days later, 100 
µL supernatant were gently removed and substituted with TCGF containing G-418 at 0.4 mg / 
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mL final volume. Additionally, the cells were transferred into flat bottom 96-well plates. On 
D7 after initial stimulation, the MBP- or OVA-specific T cells were re-stimulated: 100 µL 
supernatant were discarded and substituted with 100 µL RM containing 1.4 x 106 irradiated 
thymocytes, 7 µg / mL MBP or OVA and 0.4 mg / mL G-418. 2 days later, 50 µL TCGF with 0.4 
mg / mL G-418 were added to each well. Retroviral transduction efficiency was tested 1 or 2 
days later using an Axiovert 200M fluorescence microscope (Zeiss, Germany). Cell suspensions 
of 30 – 50 wells / plate containing T cells of bright fluorescence indicative of high transduction 
efficiency were pooled into small (5 mL) Petri dishes (Greiner Bio-One, Germany) and 1.5 mL 
TCGF were added. On D7 post-stimulation, GFP+ T cells were re-stimulated by co-culturing 3.5 
x 106 T cells with 70 x 106 irradiated thymocytes in 5 mL RM with 7 µg / mL antigen and 0.4 
mg / mL G-418. T cell proliferation was boosted 2 days later by adding TCGF and G-418. Upon 
reaching a certain cell density, the cell suspensions were diluted 2 : 3 or 3 : 4 with TCGF and 
G-418 and transferred into large (10 cm) cell culture dishes. This procedure was repeated until 
the cells started to become resting around D4 post-stimulation. In total, this 7-day T cell re-
stimulation rhythm could be repeated up to 4 times. From the 3rd re-stimulation on, T cells 
could be frozen. To this end, 20 – 50 x 106 T cell blasts (D2 after stimulation) or resting T cells 
(D6 after stimulation) were centrifuged at 1200 rpm and 4 °C for 6 min. The pellet was 
resuspended in 1.5 mL FM, transferred into freezing vials and slowly cooled down to -80 °C in 
cryoboxes (Nalgene, USA) during the course of 24 h before being transferred to liquid 
nitrogen. Whenever needed, the cells could be quickly thawed in 10 mL TCM + 10 % FCS, 
washed in EH and centrifuged at 1200 rpm and 4 °C for 6 min. Subsequently, they were either 
adoptively transferred into recipient rats or further propagated as described. 
T cell lines from TCRMBP-transgenic rats were generated and cultured as described above with 
the following exceptions: draining lymph nodes were isolated and processed 5 – 6 instead of 
9 – 10 days p.i.; T cell re-stimulation cycles were shortened to 6 instead of 7 days; and the 
antigen concentration was 5 µg / mL. 
 
2.2.3 EAE induction 
2.2.3.1 Adoptive T cell transfer 
 
Resting effector memory T cells (D6 after stimulation) specific for MBP or OVA (TMBP-EM / TOVA-
EM cells) or fully activated T cell blasts (D2 after stimulation) specific for MBP (or TMBP-blast cells) 
were resuspended in EH and brought to the desired concentration. If not stated otherwise, 
7.5 x 106 resting TMBP-EM or TOVA-EM cells, or 2.5 x 105 TMBP-blast cells per animal were transferred 
i.v. in rats briefly anesthetized with diethyl ether.  
 
2.2.3.2 Intratracheal immunization 
 
6- to 10-week-old rats that had previously received 7.5 x 106 TMBP-EM cells i.v. were briefly 
anesthetized with diethyl ether and immunized i.tr. with an emulsion consisting to equal parts 
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of guinea pig MBP (varying doses, as indicated in the results section) or OVA (0.02 mg / mL) 
and CFA (varying doses, as indicated in the results section). The emulsion was prepared as 
described above (see 2.2.2). The rats were fixed (with a bar behind their upper incisors) on a 
stand in an upright position slightly leaning backwards. The trachea was located using a Small 
Animal Laryngoscope LS-2 (Penn Century, USA). Each animal received a total volume (in µL) 
corresponding to around one third of its body weight (in g), e.g. 100 µL emulsion per 300 g 
body weight. The emulsion was instilled into the trachea through a winged 18G catheter (B. 
Braun, Germany). The animals were released from the stand and transferred to their cages to 
recover. The entire procedure typically lasted approximately 1 min per animal. 
 
2.2.3.3 Subcutaneous immunization 
 
6- to 10-week-old rats that had previously received 7.5 x 106 TMBP-EM cells i.v. were briefly 
anesthetized with diethyl ether and immunized with an emulsion consisting to equal parts of 
guinea pig MBP or OVA (1 mg / mL) and CFA (1 mg / mL). The emulsion was prepared as 
described (see 2.2.2) and injected subcutaneously into the popliteal cavities of both hind 
limbs. In total, each animal received a volume (in µL) corresponding to around one-third of its 
body weight (in g), e.g. 100 µL emulsion per 300 g body weight. Subsequently, the animals 
were returned to their cages to recover. The entire procedure typically lasted approximately 
1 min per animal. 
 
2.2.3.4 EAE scoring system 
 
After EAE induction, animals were weighed and their clinical symptoms assessed daily as 
follows: 
Score  Symptoms 
0 No clinical symptoms 
1 Tail paralysis 
2 Ataxia 
3 Hind limb paralysis 
4 Tetraparesis 
5 Moribund 







2.2.4 Organ retrieval and processing  
2.2.4.1 Preparation of single cell suspensions from different organs 
 
Animals were sacrificed by CO2 asphyxiation. Organs of interest were retrieved, weighed and 
subsequently brought to single cell suspension as described below. If not stated otherwise, all 
organs were kept on ice in EH until processed.  
Blood 
Blood was retrieved from the heart by cardiac puncture with syringes prefilled with 0.2 mL of 
Na2xEDTA (80 mmol / L; Roth, Germany) and mixed 1:1 with 1x PBS (RT). The samples were 
underlayed with 3 mL of LSM1077 (PromoCell, Germany) and centrifuged for 30 min at 2000 
rpm and RT with minimum acceleration and brake settings. The lymphocyte-enriched 
interphase was aspired, washed with EH and centrifuged at 1200 rpm and 4 °C for 6 min 
(standard washing procedure). The pellets were resuspended in 1 mL ACK buffer and 
incubated for 4 minutes on ice for erythrolysis. The samples were washed again with EH and 
taken up in 1 mL EH + 2 mM Na2xEDTA and passed through 70 µm filter caps into FACS tubes. 
Lung 
Lungs were thoroughly and repeatedly sectioned using a tissue chopper (McIlwain, UK). The 
homogenized tissue was washed with EH as described above. Pellets were resuspended and 
incubated with 2 mL of 0.3 % collagenase in 1x PBS for 30 min at 37 °C under constant shaking. 
Subsequently, the tissue was forced through a cell strainer (40 µm) and washed with EH as 
described above. The pellet was resuspended in 5 mL 40 % percoll and underlayed with 5 mL 
70 % percoll. After 30 min of centrifugation at 2000 rpm and 4 °C with minimum acceleration 
and brake settings, the leukocyte-enriched interphase was aspired and washed with EH as 
described. Finally, the pellets were resuspended in 1 mL EH + 2 mM Na2xEDTA and passed 
through 70 µm filter caps into FACS tubes. 
Lymph nodes 
Lymph nodes were passed through a cell strainer (40 µm), washed with EH and taken up in 1 
mL EH + 2 mM Na2xEDTA and passed through 70 µm filter caps into FACS tubes. 
Spleen 
Spleens were passed through a cell strainer (40 µm), washed with EH, resuspended in 5 mL 
ACK buffer and incubated for 4 minutes on ice for erythrolysis. The samples were washed 
again with EH and taken up in 5 mL EH + 2 mM Na2xEDTA. One mL of the final suspension was 
passed through 70 µm filter caps into a FACS tube. 
Spinal cord 
Spinal cords were passed through a cell strainer (40 µm) and taken up in 15 mL of EH. Cell 
suspensions were mixed with 5 mL isopercoll, underlayed with 5 mL underlay percoll and 
centrifuged for 30 min at 2780 rpm and 4 °C. The leukocyte-enriched interphase was aspired 
and washed with EH. Finally, the pellets were resuspended in 1 mL EH + 2 mM Na2xEDTA and 
passed through 70 µm filter caps into FACS tubes. 
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2.2.4.2 Isolation of antigen-presenting cells from the lung to stimulate TMBP-EM cells 
 
Lung were isolated, sectioned, digested with 0.3 % collagenase and passed through a cell 
strainer (40 µm) as described above (see 2.2.4.1) with the exception that APC isolation buffer 
was used for all washing steps instead of EH. Subsequently, the samples were centrifuged at 
1200 rpm and 4 °C for 6 min. The supernatant was aspired and the pellet resuspended in 10 
mL APC isolation buffer and underlayed with 3 mL of 14.5 % Nycodenz solution. Gradient 
centrifugation was performed for 25 min at 450 x g and RT. The interphase was collected, 
washed with APC isolation buffer and centrifuged at 1200 rpm and 4 °C for 6 min. The pellet 
was resuspended in 1 mL RM. Subsequently, the composition of the isolated cell fraction was 
determined using antibody labeling and flow cytometry (see 2.2.8.1 and 2.2.8.2). In addition, 
the isolated cells were tested for their capacity to activate T cells. 5 x 104 GFP+ TMBP-EM cells 
and 1 x 105 isolated lung cells were co-incubated in 100 µL RM with 10 µg / mL MBP in flat 
bottom 96-well plates. Two days later, 2.5 x 105 TMBP-GFP cells were adoptively transferred into 
naïve recipient rats and the clinical course of EAE was monitored over the following days. 
 
2.2.4.3 Sorting of endothelial cells from spinal cord parenchyma and meninges 
 
Spinal cord parenchyma was brought to single cell suspension using a Dounce homogenizer 
and taken up in 50 mL EH. Meninges were manually cut into small pieces and taken up in 15 
mL EH. The samples were centrifuged at 1200 rpm and 4 °C for 6 min. The supernatant was 
aspired and the parenchyma and meninges pellets taken up in 1 and 0.5 mL digestion buffer, 
respectively. The samples were incubated at 37 °C for 1 h and resuspended every 10 min. 
Subsequently, the reaction was stopped by adding 15 mL of EH + 2 mM Na2xEDTA. The cell 
suspensions were passed through 70 µm cell strainers and mixed with 5 mL isopercoll. The 
samples were centrifuged for 30 min at 2780 rpm and 4 °C. The supernatant was discarded 
and the pellets resuspended in 100 µL 1x PBS. Subsequently, the endothelial cells were 
antibody-labelled and sorted using fluorescence-activated cell sorting (see 2.2.8.1 and 
2.2.8.3). The sorted cells were centrifuged at 4000 rpm and 4 °C for 4 min and the pellet was 
resuspended in 200 µL TRI reagent (Merck, Germany) and 1 µL glycogen (Roche, Switzerland). 
The samples were stored at -80 °C until further processed. Gene expression was determined 
using qPCR (see 2.2.9). 
 
2.2.5 Re-transfer of TMBP cells from spleen 
 
TMBP-EM cells that had been transferred and activated via intratracheal immunization were 
isolated from donor animals 3.5 days p.i and transferred into naïve recipient rats. Briefly, the 
spleens were retrieved and prepared as described above (see 2.2.4.1). After the erythrolysis, 
the cells suspension of each spleen was taken up in 10 mL TCM and incubated in petri dishes 
for 30 min at 37 °C and 10 % CO2 allowing the adhesion of macrophages to the plates. This 
way, the cell suspension was enriched for non-adherent cells such as lymphocytes. The 
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resulting cell suspension was subsequently washed in EH and centrifuged at 1200 rpm and 4 
°C for 6 min. The pellet was taken up in 1 mL EH and passed through 70 µm filter caps into 
FACS tubes. The suspensions of each group were pooled and the number of contained GFP+ 
TMBP cells determined using flow cytometry (see 2.2.8.2). Subsequently, the cell suspensions 
of each group were brought to a concentration of 2.5 x 106 GFP+ TMBP cells / mL with EH. Finally, 
1 mL of suspension per animal was injected i.v. into naïve recipients. 
 
2.2.6 Lung and gut microbiota identification 
2.2.6.1 Intratracheal administration of neomycin 
 
Rats were briefly anesthetized and intubated as described above (see 2.2.3.2). A total volume 
of 150 µL neomycin (0.1, 1 or 5 mg; Thermo Fisher Scientific, USA) dissolved in sterile 1x PBS 
or sterile 1x PBS alone was instilled into the trachea through a winged 18G catheter (B. Braun, 
Germany). The animals were released from the stand and transferred to their cages to 
recover. The entire procedure typically lasted approximately 1 min per animal.  
 
2.2.6.2 Bronchoalveolar lavage 
 
Bronchoalveolar lavage (BAL) was performed under sterile conditions on animals that had 
been treated with neomycin of varying concentrations or sterile 1x PBS for 7 days. Briefly, the 
rats were sacrificed using CO2. Under the laminar flow hood and after carefully disinfecting 
the animal´s fur with 70 % EtOH, a tracheotomy was performed and a sterile gavage needle 
inserted into the trachea. The gavage needle was fixed and held in position using surgical 
suture (B. Braun, Germany). 5 mL pre-warmed (37 °C) 1x PBS were slowly instilled into the 
lung and after 30 s a volume of 4 mL was retrieved. This step was repeated once, yielding 8 
mL of total BAL fluid per animals. The samples were snap-frozen on dry ice in 2 mL aliquots 
and stored at -80 °C until further processed. 
 
2.2.6.3 DNA isolation from bronchoalveolar lavage (BAL) fluid 
 
To efficiently extract DNA from both Gram-positive and Gram-negative bacteria, a pre-lysis 
step was performed by incubating 400 µL BAL fluid with 2 µL fresh chicken egg lysozyme (100 
mg / mL; Serva, Germany) at 37 °C and 180 rpm for 1 h.  
Subsequently, DNA was isolated using the QIAamp cador Pathogen Mini Kit (QIAGEN, 
Netherlands) according to the manufacturer’s instructions. In the final step, isolated DNA was 




2.2.6.4 DNA isolation from fecal samples  
 
To homogenize the fecal samples, about 150 mg of material was incubated in 1 mL InhibitEX 
buffer (QIAGEN, Netherlands) at 37 °C for 15 min. The samples were then homogenized using 
an inoculation loop and incubated at 37° C for another 5 min. Subsequently, DNA was isolated 
using the QIAamp Fast DNA Stool Mini Kit (Netherlands, Germany) according to the 
manufacturer´s instructions. In the final step, isolated DNA was eluted in 200 µL sterile H2O. 
 
2.2.6.5 BAL fluid and fecal sample DNA quantification 
 
The isolated DNA was quantified and its purity determined based on the 260/280 ratio using 
the NanoDrop-ND1000 (Thermo Fisher Scientific, USA). The Nanodrop was first cleaned using 
5 µL and calibrated using 2 µL of sterile H2O. Subsequently, 2 µL of each sample were 
measured.  
 
2.2.6.6 Gel electrophoresis 
 
Extraction of metagenomic DNA and amplicon production were verified via gel 
electrophoresis. Agarose gel was prepared by boiling 0.8 % low-electroendosmosis (LE)-
Agarose (Biozym, Germany) in 1x TAE. The agarose was filled into a gel electrophoresis 
chamber which was filled with 1x TAE after polymerization of the gel. The pockets of the gel 
were loaded with 4 µL DNA sample and 2 µL 6 x Orange DNA Loading Dye (Thermo Fisher 
Scientific, USA). 2 µL of GeneRuler 1 kb DNA ladder (Thermo Scientific, USA) flanking the DNA 
samples were used as size reference. Electrophoresis was performed at 100 mV for 50 min. 
The gel was subsequently stained in an ethidium bromide bath (0.5 µg / mL) for 10 min 
allowing the ethidium bromide to intercalate between the DNA base pairs. Afterwards, the 
stained DNA molecules were visualized with ultraviolet light (302 nm) using the ImageQuant 
100 image capture system (GE Healthcare, USA / Amersham Biosciences, UK). 
 
2.2.6.7 PCR amplification of bacterial amplicons 
 
The 16S rRNA region is highly conserved among bacteria and thus allows for the determination 
of bacterial strains and phylogeny (Janda and Abbott, 2007). Bacterial 16S rRNA amplicons 
were amplified via PCR using the bacterial primers targeting the V3 – V4 region described by 








Table 2: Primer-sequences of 16S rRNA V3 – V4 region 





Bold = binding sequence / cursive = MiSeq overhang 
 
For each PCR reaction, a master mix was prepared as follows: 
 
Table 3: Master mix for amplicon PCR 
Reagent Volume (µL) / reaction 
5x Phusion GC Buffer 10 
10 mM dNTPs 1 
DMSO 2.5 
MgCl2 0.2 
MiSeq_B_V3_for_klindworth primer (10 µM) 1 
MiSeq_B_V4_rev_klindworth primer (10 µM) 1 
Phusion polymerase 0.5 
Template DNA 7 µL BAL fluid / 6 µL feces 
Nuclease-free H2O ad 50 µL 
 
For each reaction, 43 µL master mix and 7 µL or 6 µL template DNA (100 – 150 ng) for BAL 
fluid and feces, respectively, were gently mixed in cooled PCR reaction tubes. For the negative 
control 7 µL nuclease-free H2O and for the positive control 7 µL of B. thuringiensis BTI18246 
DNA (diluted 1:7 with nuclease-free H2O) were used instead of DNA isolated from BAL fluid or 
feces. The reaction tubes were placed in a Mastercycler Nexus Gradient thermo cycler 
(Eppendorf, Germany). The PCRs were performed in triplicates with the following cycler 
settings (Table 4): 
 
Table 4: PCR cycler settings 
Step Temperature (°C) Time (s) Cycles 
Initial denaturation 98 60 1x 
Denaturation 98 45  
25x (feces) /  
35x (BAL fluid) 
Annealing 62 45 
Elongation 72 30 (feces) / 45 (BAL fluid) 
Final elongation 72 300 1x 
Hold 4 ∞  
 
The amplicon synthesis was subsequently tested using 0.8 % gel electrophoresis as described 
above (see 2.2.6.6).  
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2.2.6.8 Purification of amplicon DNA  
 
The amplified DNA was purified to remove unwanted side products and reagents using the 
MagSi-NGS Plus Kit (MagnaMedics, Netherlands) according to the manufacturer’s 
instructions. After purification, amplicon DNA from BAL fluid and feces samples was eluted in 
40 µL sterile H2O. The final concentration was determined using the NanoDrop as described 
above (see 2.2.6.5).  
2.2.6.9 Bacterial amplicon sequencing, data processing and data analysis  
 
Bacterial amplicon sequencing was performed at the Department of Genomic and Applied 
Microbiology and the Göttingen Genomics Laboratory of the University Göttingen under 
supervision of Prof. Dr. Rolf Daniel. Indexing of the PCR products was performed using the 
Nextera XT Index kit according to the manufacturer´s instructions (Illumina, San Diego, CA, 
USA). Sequencing of 16S rRNA amplicons was performed via the dual index paired-end 
approach (2x 300 bp) with v3 chemistry for the Illumina MiSeq platform. 
Processing of raw data and data analysis was performed by Dr. Jacqueline Hollensteiner. The 
MiSeq marker gene pipeline designed by Dr. Dominik Schneider was applied. Briefly, raw 
paired-end reads were quality-filtered using fastp (Chen et al., 2018). PEAR was used for read 
merging (Zhang et al., 2014). Subsequently, primer clipping was performed using cutadapt 
(Martin, 2011). Reads shorter than 300 bp and chimeras were filtered out using VSEARCH 
(Rognes et al., 2016). The abundance table was based on exact amplicon sequence variants 
(ASV) with 100 % similarity. The sequences were analysed via BLAST+ (NCBI, USA). The 
resulting taxonomy was entered into the abundance table. Subsampling of ASV tables, 
diversity analysis and graphical depiction of data was performed using RStudio (RStudio, USA) 
and the R packages ampvis2 (Andersen et al., 2018) and ggplot2 (Wickham, 2011). Alpha-
diversity metrics were performed in order to characterize bacterial diversity within each 
sample. These alpha-diversity metrics included the Shannon, Simpson, Invsimpson and Chao1 
indices and were plotted in Graphpad Prism (V8; GraphPad, USA). 
 
2.2.7 TMBP-EM cell activation and proliferation assay 
 
The activation and proliferation potential of TMBP-EM cells was determined in two different 
experimental setups: 
TMBP-EM cell anergy assay 
TMBP cells from mediastinal lymph nodes of animals that had previously been transferred with 
TMBP-EM cells and i.tr. immunized with high (50 µg MBP / 300 g body weight; HI) or low (1 µg 
MBP / 300 g body weight; LO-OPT) concentrations of MBP were isolated and purified by 
negative selection for CD4+ T cells (Stemcell Technologies, Canada) on D5 p.i.  
5 x 104 isolated TMBP cells and 5 x 105 irradiated thymocytes in 100 µL RM with 10 mg / mL 
(+MBP), or without antigen (-MBP) were distributed to the wells of 96-well flat bottom plates 
(Thermo Fisher Scientific, USA). To determine T cell activation on transcriptional level, the cell 
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suspensions of the corresponding wells were centrifuged at 4000 rpm and 4 °C for 4 min and 
resuspended in 300 µL TRI reagent (Merck, Germany) and 1 µL glycogen (Roche, Switzerland) 
12 h after in vitro stimulation. The samples were stored at -80 °C until further processed. 
Activation on mRNA level was quantified based on the expression of IFN and IL-17 using qPCR 
(see 2.2.9).  
To determine T cell activation on protein level, the cells were stained for surface expression 
of CD25 as described below (see 2.2.8.1) and acquired using flow cytometry (see 2.2.8.2) 48 h 
after in vitro stimulation. T cell proliferation was quantified by flow cytometry on D2, 3 and 4 
after in vitro stimulation by adding a defined number of Calibrite APC beads (BD Biosciences, 
USA) to the samples. On D2, 50 µL TCGF were added to wells measured on D3 (and 4). On D3, 
another 50 µL TCGF were added to the wells acquired on D4. 
Neomycin toxicity assay 
5 x 104 TMBP-EM cells and 5 x 105 irradiated thymocytes in 100 µL RM with 10 mg / mL were 
distributed to the wells of 96-well flat bottom plates (Thermo Fisher Scientific, USA). 
Neomycin was added in various concentration (100 ng – 100 mg / mL) to test a potential 
cytotoxic effect on T cells. The cells were incubated at 37 °C and 10 % CO2. 
T cell proliferation was quantified by flow cytometry on D2, 3 and 4 after in vitro stimulation 
by adding a defined number of Calibrite APC beads (BD Biosciences, USA) to the samples. On 
D2, 50 µL TCGF were added to wells measured on D3 (and 4). On D3, another 50 µL TCGF were 
added to the wells acquired on D4.  
Furthermore, 2.5 x 105 TMBP-blast cells (D2 after stimulation) were adoptively transferred into 
naïve recipient rats and the clinical course of EAE was monitored over the following days. 
 
2.2.8 Flow cytometry 
2.2.8.1 Cell staining 
 
Single cell suspensions from organs were prepared as described above (see 2.2.4). To stain 
immune cell populations, 100 µL single cell suspension were transferred to a conical bottom 
96-well plate (Thermo Fisher Scientific, USA). The plate was centrifuged for 3 min at 4 °C and 
1300 rpm. The cells were washed with 1x PBS, centrifuged again and blocked with FACS buffer 
on ice for 3 min. The plate was again centrifuged and the cells resuspended in primary 
antibody mixes diluted in FACS buffer (antibodies and dilutions listed under 2.1.4). The 
samples were incubated on ice and protected from light for 30 minutes. In case a secondary 
antibody staining was performed, the washing, blocking and staining steps were repeated. 
Finally, the cells were centrifuged and taken up in 100 µL FACS buffer. The samples were 





2.2.8.2 Flow cytometry cell quantification 
 
A defined number of Calibrite APC beads (BD Biosciences, USA) was added to 100 µL cell 
suspension from culture or from organs prepared as described (see 2.2.4) containing 
fluorescent TMBP cells or antibody-stained immune cell populations (Fig. 5). The samples were 
acquired using a FACSCalibur (BD Biosciences, USA) or a CytoFLEX S (Beckman Coulter, USA). 
Data analysis was performed using FlowJo (BD Biosciences, USA). In order to quantify a cell 
population, cell number and number of added beads were correlated and normalized to 
sample volume or organ weight if applicable. 
Fig. 5 shows the exemplified gating strategies used for the flow cytometry acquisition of 
different immune cell populations. 
 
2.2.8.3 Flow cytometry cell sorting 
 
Single cell suspensions from organs were prepared as described (see 2.2.4). GFP+ TMBP cells 
(from lung, mediastinal lymph nodes, blood and spinal cord) or endothelial cells (from spinal 
cord meninges or parenchyma) were sorted using a FACSAria III (BD Biosciences, USA) at a low 
flow rate. The cells were collected in EH-prefilled collection tubes under constant cooling (4 
°C). Typically, in order to perform qPCR, 300 – 5000 T cells or 300 – 3000 endothelial cells were 
sorted. 
In case T cells were sorted for next-generation sequencing (NGS), the single cell suspensions 
of 3 – 4 animals were pooled and CD11b+ cells were depleted prior to sorting using Anti-PE 
MicroBeads for MACS separation (Miltenyi Biotech, Germany) according to the 
manufacturer´s instructions. This way the samples were enriched for lymphocytes and a total 
of 20,000 cells was sorted. Finally, the sorted cells were centrifuged at 4000 rpm and 4 °C for 
4 min and the pellet was resuspended in 300 µL TRI reagent (Merck, Germany) and 1 µL 
glycogen (Roche, Switzerland). The samples were stored at -80 °C until further processed. 
Gene expression was determined using qPCR (see 2.2.9). 
















Figure 5: Gating strategy for flow cytometry acquisition of different immune cell populations. Depicted are the exemplified 
gating strategies used for the analysis and quantification of different immune cell types. (A) General gating strategy to roughly 
distinguish lymphocytes and monocytes from granulocytes and APC beads. (B) Gating for APC beads used for the 
quantification of cell populations. (C) Gating for GFP+ TMBP cells. (D – H) Gating strategies and surface marker combinations 
used for antibody labeling of (D) CD4+ T cells, (E) CD8a+ T cells, (F) B cells, (G) different subgroups of myeloid cells and (H) 
neutrophils. The gating strategy is color-coded: identical colors of gate and frame indicate parent population and 
subpopulation, respectively. The antibodies used for cell surface marker stainings are listed in Table 1. 
29 
 
Figure 6: Gating strategy for fluorescence-activated sorting of GFP+ TMBP cells and spinal cord endothelial cells. Depicted 
are the exemplified gating strategies used for the flow cytometry sorting of (A) GFP+ TMBP cells and (B) spinal cord endothelial 
cells. The gating strategy is color-coded: identical colors of gate and frame indicate parent population and subpopulation, 




2.2.9 RNA isolation, cDNA synthesis and quantitative real-time PCR 
 
Gene expression on transcription level was determined using quantitative real-time PCR 
(qPCR). RNA isolation from sorted T cells or total tissues that had been stored in TRI Reagent 
(Merck, Germany) at -80 °C was performed according to the manufacturer´s instructions. 
Reverse transcription into cDNA was performed using the RevertAid First Strand cDNA 
synthesis kit (Thermo Fisher Scientific, USA) according to the manufacturer´s instructions. 
qPCR was performed on an Applied Bioystems StepOnePlus Real-Time PCR system (Thermo 
Fisher Scientific, USA) using target-specific TaqMan probes quenched with TAMRA and labeled 
with FAM (Thermo Fisher Scientific, USA). -actin served as house-keeping gene. All 
measurements were performed in duplicates. The following primers and probes were used:  
 
Table 5: List and sequences of qPCR primers 
Gene (Abbreviation) Forward primer (5´-3´) Reverse primer (5´-3´) Probe (FAM-5´-3´-TAMRA) 
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2.2.10 Next-Generation Sequencing of sorted T cells 
 
Next-generation sequencing (NGS) of the transcriptome of sorted TMBP cells was performed at 
the Transcriptome and Genome Analysis Laboratory (TAL) of the University Medical Center 
Göttingen (UMG) under supervision of Dr. Gabriela Salinas. Sequencing data analysis was 
performed by Dr. Orr Shomroni. Additional statistical analysis and graphical depiction was 
performed by Dr. Francesca Odoardi, Michael Haberl and Leon Hosang using Microsoft Excel 
(2010, 2016; Microsoft, USA) and GraphPad Prism (V8; GraphPad, USA). Principle component 
analysis (PCA) was performed using R (V3.6.0; R Core Team). Biological processes Gene 
Ontology (GO) term enrichment analysis was performed using DAVID (V6.8; LHRI, USA). 
 
2.2.11 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism (V6 – 8; GraphPad, USA) and 
Microsoft Excel (2010 and 2016; Microsoft, USA). Unless differently indicated, data are 
represented as mean ± SEM (standard error of the mean). The statistical tests underlying data 
analysis are stated in the corresponding figure legends. In some graphs, the data from two 
independent experiments were combined provided they were not significantly different. To 
this end, Gaussian distribution of each independent set of data was tested using a 
Kolmogorov–Smirnov test with Lilliefors’ correction. In case of normal distribution, intergroup 
comparisons were analyzed using two-tailed unpaired t-tests. In case the number of animals 
per experiment was not sufficient to test for Gaussian distribution or the data were not 
normally distributed, intergroup comparisons were performed using the non-parametric 
Mann-Whitney test. Data of two experiments were only combined if no significant difference 
was observed. 



















3.1. TMBP-EM cell activation and EAE induction via the lung 
3.1.1 Establishment and characterization of an i.tr. induced EAE model 
3.1.1.1 Intratracheal immunization with low doses of MBP induces EAE 
 
In order to examine the potential role of the lung in triggering CNS autoimmunity, we first 
aimed to establish an aEAE model based on the activation of MBP-specific T effector memory 
(TMBP-EM) cells within the lung. To this end, 7.5 x 106 TMBP-EM cells (resting TMBP cells, D6 after in 
vitro antigen encounter) were i.v. transferred into naïve recipient animals. 6 – 12 h later, the 
rats were i.tr. immunized with MBP emulsified in CFA (Fig. 7A).  
The CFA dose commonly used for s.c. immunization in aEAE is 150 µg / animal (average body 
weight: 150 – 200 g). For i.tr. immunization, a starting dose of 50 µg / 300 g body weight was 
chosen because it was well-tolerated by the animals. The standard MBP concentration used 
for s.c. immunization in aEAE is 75 µg / animal. Limited by instillation volume and MBP stock 
concentration, we chose a maximum dose of 50 µg MBP / 300 g body weight as starting point. 
We then performed a dose titration in order to identify the most effective antigen dose. 
Therefore, the animals were i.tr. immunized with MBP doses ranging from 0.01 µg to 50 µg / 
300 g body weight emulsified in 50 µg CFA / 300 g body weight 6 – 12 h following TMBP-EM cell 
transfer. 
On D1 post-immunization (p.i.), all tested groups showed body weight losses between 6 – 10 
%. Between D2 and D3 p.i., the weight of all groups started to increase again (Fig. 7B). While 
the body weight of the groups immunized with the lowest (0 and 0.01 µg / 300 g body weight) 
and the highest MBP concentrations (50 µg / 300 g body weight) steadily increased over the 
following days, the body weight of the other groups (0.1, 1 and 10 µg MBP / 300 g body weight) 
began to stagnate and slightly decrease on D4 p.i. and during the following 2 – 3 days (Fig. 7B). 
Coinciding with this second period of weight loss, some animals began to exhibit first clinical 
symptoms between D5 and D6 p.i. (Fig. 7D).  
Interestingly, only the animals immunized with MBP at a dose of 1 µg / 300 g body weight 
developed a severe EAE with an incidence of 100 % (Fig. 7C) and an average peak score of 2.7 
± 0.15 on D7 p.i. (Fig. 7E). 
Mild EAE with peak scores of slightly less than 1 and reduced incidence was induced in the 
groups immunized with 10x higher (75 % incidence, peak score 0.88 ± 0.38) and 10x lower (50 
% incidence, peak score 0.88 ± 0.41) MBP concentrations (Fig. 7C, E). 
The highest MBP concentration tested (50 µg / 300 g body weight) resulted in the induction 
of EAE in merely 40 % of animals (Fig. 7C). In these animals, EAE was significantly delayed and 
its severity was particularly low: Clinical symptoms started between D7 and D8 p.i. (Fig. 7D) 
and the average peak score was 0.55 ± 0.54 (Fig. 7E). In all groups the clinical symptoms 




Figure 7: Titration of the MBP concentration used for i.tr. immunization. (A) Experimental design: Rats received 7.5 x 106 
TMBP-EM-GFP cells i.v. and were i.tr. immunized 6 – 12 h later with a fixed dose of CFA (50 µg / 300 g body weight) and varying 
doses of MBP (0, 0.01, 0.1, 1, 10, 50 µg / 300 g body weight). (B) Body weight change (lines) and clinical scores (bars) over the 
course of EAE. (C) Incidence (%). (D) Average onset (days p.i.). (E) Average peak score. (F) Average cumulative score. 
Cumulative data from five independent experiments. Values are represented as mean ± SEM. Statistical significance was 
determined via one-way ANOVA with Tukey´s multiple comparisons test. *p < 0.05; **p < 0.01; ***p < 0.001.  
 
3.1.1.2 Moderate CFA concentrations are sufficient to induce EAE via the lung 
 
In order to optimize the protocol, we next titrated the CFA concentration used for i.tr. 
immunization. To this end, the rats were i.tr. immunized with the previously determined 
optimal MBP dose (1 µg / 300 g body weight) and varying CFA concentrations ranging from 50 
µg down to 1 µg / 300 g body weight following TMBP-EM cell transfer.  
Between D4 and D5 p.i., the 50, 25, 10 and 5 µg CFA groups started exhibiting weight 
stagnation or loss, preceding the onset of first clinical symptoms starting between D5 and D6 
p.i. (Fig. 8A – C). In the subsequent days, a severe EAE developed in all 4 groups, reaching 
average peak scores between 2.58 and 2.81 on D7 p.i. and average cumulative scores ranging 
from 9.5 to 11.4 (Fig. 8D – E). On D8 / D9 p.i., clinical symptoms started to decrease and the 
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animals fully recovered by D11 p.i. (Fig. 8A). Animals treated with 1 and 0 µg CFA did not show 
any signs of EAE.  
In summary, we observed that very low doses of antigen (75 – 150-fold reduced compared to 
the dose used for s.c. immunization) and of adjuvant (15 – 30-fold reduced compared to the 
dose used for s.c. immunization) can induce a severe EAE when delivered i.tr. Mild EAE could 
still be induced with 750 – 1500-fold reduced doses of MBP compared to s.c. immunization. 




Figure 8: Titration of the CFA concentration used for i.tr. immunization. Rats received 7.5 x 106 TMBP-EM-GFP cells i.v. and were 
i.tr. immunized 6 – 12 h later with a fixed dose of MBP (1 µg / 300 g body weight) and varying doses of CFA (0, 1, 5, 10, 25, 50 
µg / 300 g body weight). (A) Body weight change (lines) and clinical scores (bars) over the course of EAE. (B) Incidence (%). 
(C) Average onset (days p.i.). (D) Average peak score. (E) Average cumulative score. Cumulative data from four independent 
experiments. nd = not determined. Values are represented as mean ± SEM. Statistical significance was determined via one-
way ANOVA with Tukey´s multiple comparisons test. ***p < 0.001. 
 
3.1.1.3 Immunization with a low MBP concentration induces EAE in memory rats 
 
The newly established protocol of TMBP-EM cell activation via the lung (lung EAE model) is based 
on a relatively high number of transferred T cells (7.5 x 106) and a relatively short time interval 
between transfer and immunization (6 – 12 h). To test whether the highly reduced doses of 
antigen and adjuvant (1 µg MBP and 10 µg CFA / 300 g body weight) could trigger CNS disease 
in a more physiological setup, we i.tr. immunized a group of memory rats (Fig. 9A) in which 
transferred TMBP-EM cells persist lifelong in very low frequencies in primary lymphatic organs 
but also in the lung (Kawakami et al., 2005). 
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In line with the previous results, all animals developed EAE. After an initial weight loss of 8 % 
following immunization, the animals´ body weight started to increase again between D2 and 
D4 p.i., before a second episode of weight loss lasting until D9 p.i. started. This second episode 
of weight loss was accompanied by the emergence of first clinical symptoms on D6 p.i. EAE 
reached its average peak score of 2.25 ± 0.14 on D7 p.i. before symptoms started vanishing 
again. The animals fully recovered by D12 p.i (Fig. 9B).  
 
 
Figure 9: I.tr. immunization of memory rats with a low MBP dose. (A) Experimental design: Memory rats were generated by 
neonatal i.p. transfer of 2 x 106 TMBP-EM-GFP cells. After 6 – 8 weeks, the animals were i.tr. immunized with 1 µg MBP and 10 µg 
CFA / 300 g body weight. (B) Body weight change (lines) and clinical scores (bars) over the course of EAE. 
 
3.1.1.4 Kinetic of TMBP cell distribution during i.tr. induced EAE 
 
We went on to further characterize the newly established lung EAE model. To this end, 
distribution (Figs. 10 and 11) and activation state (Figs. 10 and 12) of transferred T cells in 
different organs was determined on different days following i.tr. immunization. Based on the 
previous clinical results (Fig. 7), animals were immunized with the following antigen doses: 50 
µg MBP (high; HI); 1 µg MBP (low-optimal; LO-OPT); 0.01 µg MBP (low-suboptimal; LO-SUB; 
all concentrations per 300 g body weight). Furthermore, we included two control groups: one 
group received T cells without being immunized (naïve; NAI); the other group was immunized 
with CFA only (CFA). Animals were sacrificed before immunization (D0; 12 h p.t.), on D1 
(expected time point of T cell activation), D3 (expected time point of ongoing T cell 




Figure 10: Experimental scheme for the kinetic of TMBP cell distribution during i.tr. induced EAE. The animals received 7.5 x 
106 TMBP-EM-GFP cells and were i.tr. immunized 6 – 12 h later with the indicated combinations of MBP and CFA (per 300 g body 
weight). Lung, mediastinal and inguinal lymph nodes, spleen blood and spinal cord (CNS) were removed on D0, D1, D3, D5 
and D7 p.i. The organs were processed and the amount of transferred T cells determined using flow cytometry. T cells were 
additionally sorted from lung, mediastinal lymph nodes, blood and spinal cord. The expression of IFN and IL-17 was 
determined as read-out for activation using qPCR. NAI = naïve; CFA = adjuvant only; LO-SUB = low-suboptimal MBP dose; LO-
OPT = low-optimal MBP dose; HI = high MBP dose. 
 
As expected based on the previous results, a severe EAE was only induced in the animals 
immunized under LO-OPT antigen conditions. The LO-SUB and HI group only developed mild 
EAE characterized by a reduced incidence, delayed onset and a low average peak score (Fig. 
11A – D).  
FACS quantification of transferred T cells in the different organs revealed that T cell numbers 
in the peripheral organs generally increased in a dose-dependent manner with the highest 
number of cells observed in the HI group. In striking contrast, in the spinal cord, the highest 
number of infiltrated T cells was observed in the LO-OPT group (Fig. 11E – K). 
In more detail, the number of transferred T cells in the lung on D1 p.i. was low and comparable 
between the different groups. First significant differences started to emerge on D3 p.i. While 
T cell numbers in all groups gradually increased, the highest numbers were observed in the HI 
group, followed by the LO-OPT group. T cell numbers reached their peak on D5 p.i., and the 
antigen dose-dependent increase became even more obvious. On D7 p.i., the trend of a dose-
dependent T cell number continued, though cell numbers in general were going down again 
(Fig. 11E). 
In the lung-draining mediastinal lymph nodes, barely any cells could be observed in any of the 
groups on D0 and D1 p.i. On D3 p.i., a strong and dose-dependent increase could be observed 
in the LO-OPT and the HI group. In comparison, only few T cells were found in the LO-SUB, CFA 
and NAI groups. On D5 and D7 p.i., T cell numbers in the mediastinal lymph nodes of the HI 
and the LO-OPT group decreased again but remained higher than in the other groups (Fig. 
11F). 
In the non-draining inguinal lymph nodes, a gradual increase in T cell numbers was observed 
over the course of the experiment. This increase was comparable between the experimental 
groups, with a slight tendency toward a higher number in the HI group (Fig. 11G). 
In the spleen, very few T cells were detectable in all groups on D0 and D1 p.i. On D3 p.i., T cell 
numbers started to increase in a dose-dependent manner and peaked on D5 p.i., shortly 
before EAE onset. The by far highest number of T cells was observed in the spleen of the HI 
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group, followed by the LO-OPT group. The T cell number of the LO-SUB group was by trend 
but not significantly higher than in the CFA and NAI group. On D7 p.i., the cell numbers had 
again decreased to a comparable number in all groups but the HI group (Fig. 11H).  
In the blood only few cells could be observed in all groups on D0 and D1 p.i. Starting on D3 
p.i., T cell numbers started increasing in an MBP dose-dependent manner. Cell numbers in all 
groups peaked on D5 p.i., just before the onset of EAE. The highest T cell numbers were 
observed in the HI group followed by the LO-OPT group whereas numbers in the NAI, CFA and 
LO-SUB groups were comparable. On D7 p.i., the T cell numbers of all groups had decreased 
to a similarly low level with exception of the LO-SUB group, which showed slightly increased 
numbers (Fig. 11I). 
Between D0 and D3 p.i., no T cells were observed in the spinal cord of any of the groups. On 
D5 and D7 p.i., T cells were detected in spinal cords of the LO-SUB, LO-OPT and HI but not the 
NAI and CFA groups. Despite the high number of cells observed in the blood of the HI group 
on D5 p.i., only a minor proportion entered the spinal cord (Fig. 11J, K). In contrast and in line 
with the clinical course of EAE, the T cell number was almost 10x higher in the LO-OPT group. 
On D7 p.i., the T cell numbers detected in the CNS of the LO-SUB and the LO-OPT group 
remained similar compared to D5 p.i. In contrast, T cell infiltration into the CNS of the HI group 
further increased (Fig. 11J, K). No T cells could be detected in the CNS of the NAI and the CFA 




Figure 11: Characterization of TMBP cell distribution in different organs during i.tr. induced EAE. Rats received 7.5 x 106 TMBP-
EM-GFP cells and were i.tr. immunized 6 – 12 h later with varying doses of MBP (0 µg: NAI and CFA; 0.01 µg: LO-SUB; 1 µg: LO-
OPT; 50 µg: HI; all per 300 g body weight) and CFA (0 µg: NAI; 10 µg: rest; all per 300 g body weight). (A) Body weight change 
(lines) and clinical scores (bars) over the course of EAE. (B) Incidence (%). (C) Average onset (days p.i.). (D) Average peak score. 
(E – J) Transferred T cells per g or mL detected in the indicated organs at indicated time points p.i. (K) Infiltration rate: T cells 
in spinal cord (CNS; /g) / T cells in blood (/mL) on D5 and 7 p.i. Cumulative data from three independent experiments. Number 
of animals for the EAE clinical outcome as indicated. Number of animals for T cell quantification: 4 – 8 / group and time point. 
nd = not determined. Values are represented as mean ± SEM. Statistical significance was determined via one-way ANOVA 





3.1.1.5 Kinetic of TMBP cell activation during i.tr. induced EAE 
 
In addition to their distribution, we determined the activation state of the transferred T cells 
at different time points in different organs throughout the course of i.tr. induced EAE. The 
experimental setup was identical to the previous part (see 3.1.1.4 and Fig. 10).  
On D1 p.i., a clear upregulation of both IFN and IL-17 expression was observed in T cells from 
the lung of the HI group. The expression of both genes was significantly higher than in the NAI, 
CFA and LO-SUB but not the LO-OPT group (Fig. 12A). IFN and IL-17 expression of T cells 
sorted from lungs of the LO-OPT group also tended to be higher than in the NAI, CFA and LO-
SUB group. This difference, however, was not significant (Fig. 12A). On D3 p.i., expression of 
both IFN and IL-17 in the HI and the LO-OPT group had decreased again and was 
indistinguishable from the NAI, CFA and LO-SUB groups (Fig. 12A). 
Barely any T cells could be observed in or sorted from the mediastinal lymph nodes on D0 and 
D1 p.i. Expression of both IFN and IL-17 on D3 and D5 p.i. was decreased by a factor of around 
10 compared to T cells sorted from the lung at the same time points (Fig. 12B). A significantly 
higher expression of IFN was detected in T cell from the NAI group compared to the other 
groups on D3 p.i. (Fig. 12B). Apart from this, the expression of IFN and IL-17 was similar 
between the different groups (Fig. 12B). 
T cells from the spinal cord (CNS) could only be sorted from the LO-OPT and HI group. On D5 
p.i., the expression of IFNand IL-17 in the LO-OPT group was strongly upregulated by a factor 
of almost 3 compared to the HI group (Fig. 12C). On D7 p.i., the expression of both IFN and 




Figure 12: Kinetic of cytokine expression in TMBP cells during i.tr. induced EAE. Experimental setup as in Fig. 11. Activation 
of transferred T cells sorted from lung (A), mediastinal lymph nodes (Med LN; B) and spinal cord (CNS; C) at the indicated 
time points (days p.i.) was determined on mRNA level using qPCR based on the expression of IFNleft) and IL-17 (right). 
Expression (2-ΔCT) was normalized to -actin expression of the same samples. N = 2 – 5 / group and time point. nd = not 
determined. Values are represented as mean ± SEM. Statistical significance was determined via one-way ANOVA with Tukey´s 
multiple comparisons test (A, B) or unpaired two-tailed t-test (C). *p < 0.05; **p < 0.01. 
 
In addition, we determined the total tissue expression of IFN and IL-17 in the corresponding 
lung and CNS samples. Similar to the sorted T cells, the expression of both IFN and IL-17 
tended to by upregulated in the lung tissue of the HI group on D1 p.i., though it was not 
significantly different from the other groups (Fig. 13A). On D3 p.i., IFN and IL-17 expression 
was again similar in all groups (Fig. 13A). 
In the CNS, a significant upregulation in IFN expression and a strong tendency toward a higher 
expression of IL-17 was observed on D5 p.i in the LO-OPT group compared to the HI group 
(Fig. 13B). On D7 p.i., the expression of IFN and IL-17 in the LO-OPT group had decreased 
again. In contrast, IFN expression in the CNS of the HI group tended to be upregulated, 
though this difference was not significant. IL-17 expression was similar between the LO-OPT 
and HI group on D7 p.i. (Fig. 13B). 
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Figure 13: Kinetic of cytokine expression in lung and spinal cord during i.tr. induced EAE. Experimental setup as in Fig. 11. 
Total tissue expression of IFN (left) and IL-17 (right) mRNA in lung (A) and spinal cord (CNS; B) at the indicated time points 
(days p.i.) was determined using qPCR. Expression (2-ΔCT) was normalized to -actin expression of the same samples. N = 2 – 
5 / group and time point. Values are represented as mean ± SEM. Statistical significance was determined via one-way ANOVA 
with Tukey´s multiple comparisons test (A) or unpaired two-tailed t-test (B). *p < 0.05. 
 
3.1.1.6 Gene expression of TMBP cells is highly regulated during i.tr. induced EAE 
 
In order to achieve an in-depth characterization of the lung EAE model, transcriptome analysis 
via next-generation sequencing (NGS) was performed on transferred T cells sorted from the 
lungs before immunization (D0; 12 h p.t.) and on D1 p.i. (time point of T cell activation), as 
well as from the blood on D5 p.i. (onset of EAE). 
Principle component analysis (PCA) revealed distinct clustering of T cells sorted from lung and 
blood at each time point, indicating a substantial reprogramming in their global gene 
expression profile (Fig. 14A). More specifically, of 14,590 genes examined in total, 589 were 
found regulated in T cells sorted from the lung on D1 p.i. compared to D0. Of these 589 genes, 
412 were up- and 177 were downregulated. In the cells sorted from blood on D5 p.i. compared 
to lung on D1 p.i., 2967 genes were found differently expressed. Among these, 1376 were up- 
and 1591 were downregulated (Fig. 14B).  
Of the genes found to be regulated between D0 and D1 p.i. in the lung and between D1 p.i. in 
lung and D5 p.i. in blood, 388 were regulated in common (Fig. 14C). Interestingly, in this group 
of shared genes, all genes upregulated on D1 compared to D0 p.i. were downregulated on D5 
compared to D1 p.i. and vice versa (Fig. 14D, E), even though these corresponding mutual up- 
and downregulations were of varying extents (Fig. 14D, E). In addition to the shared regulated 
genes, a large number of genes (2579, i.e. 87 % of the regulated genes) was also found to be 
regulated independently between blood on D5 p.i. and lung on D1 p.i. (Fig. 14C). 
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We next performed biological processes Gene Ontology (GO) term enrichment analysis on the 
388 genes commonly regulated genes between D0 and D1 p.i. and between D1 and D5 p.i. 
The three most significant GO terms were cell division, chromosome segregation and mitotic 
nuclear division, all of which are crucially involved in the regulation of cell proliferation. Among 
the significant GO terms were also cellular response to IFN, inflammatory response, chronic 
inflammatory response and cellular response to TNF, which is in line with the activation of 
TMBP-EM cells observed in the lung following i.tr. immunization. Additional terms included 
chemotaxis and chemokine-mediated signaling pathway, suggestive of changes in the 
migratory mode of the transferred T cells (Fig. 14D).  
In addition, we performed biological processes GO term enrichment analysis on the 2579 
genes exclusively regulated between blood on D5 p.i. and lung on D1 p.i. The two terms most 
associated with gene expression regulation were positive regulation of telomerase RNA 
localization to Cajal bodies and positive regulation of protein localization to Cajal bodies, 
suggestive of changes in assembly and / or processing of ribonucleoprotein complexes. Other 
terms like DNA replication initiation, DNA-dependent DNA replication, positive regulation of 
DNA-directed DNA polymerase activity indicated regulation of cell proliferation. Moreover, 
the GO-term cell-cell adhesion may correlate with an increased CNS-invasive capacity of the T 
cells (Fig. 14E). Taken together, the transcriptome analysis indicates that i.tr. immunization 
induced a shift in the gene expression profile of TMBP-EM cells in the lung toward proliferation 
and activation. In T cells retrieved from the blood after exiting the lung, this profile was 
partially reversed. In addition, however, a completely different set of genes was differently 








Figure 14: Regulation of the gene expression profile of TMBP cells following i.tr. activation. Rats received 7.5 x 106 TMBP-EM-
GFP cells and were i.tr. immunized 6 – 12 h later under LO-OPT conditions (1 µg MBP and 10 µg CFA / 300 g body weight). 
Transferred T cells were sorted from lung on D0 p.i. (12 h p.t.; no immunization) and D1 p.i. and from blood on D5 p.i. 
Transcriptome analysis was performed using NGS. (A) Principal component analysis (PCA) based on the gene expression of 
the transferred T cells from the organs and time points indicated. (B) Number of regulated genes between D0 and D1 p.i. in 
lung (left) and between D1 p.i. in lung and D5 p.i. in blood (right). (C) Number of commonly and independently regulated 
genes between the indicated time points and organs. (D, E) Fold change (Log2) in the expression of the commonly regulated 
genes between D0 p.i. and D1 p.i. in lung (Lung D1 p.i.) and between D1 p.i. in lung and D5 p.i. in blood (Blood D5 p.i.). Each 
individual line represents the fold change in expression of one gene (Log2). Note that the expression of every gene 
upregulated under one condition is downregulated under the other condition and vice versa. (F, G) Biological processes Gene 
Ontology (GO) term enrichment analysis of the genes regulated [-Log10 (p-value)] commonly between D0 and D1 p.i. in lung 
and between D1 p.i. in lung and D5 p.i. in blood (F) or independently between D1 p.i. in lung and D5 p.i. in blood (G). GO term 
analysis was performed using DAVID. Cumulative data from three independent experiments with N = 3 – 4 / group and time 
point. 
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3.1.1.7 Antigen-presenting cells from the lung are capable of activating TMBP-EM cells  
 
Lung-associated activation of T cells has classically been proposed to be initiated in the lung-
draining mediastinal lymph nodes following dendritic cell-mediated antigen uptake in the lung 
and transport to this location (Sheridan and Lefrançois, 2011; Caucheteux et al., 2013; 
Lambrecht et al., 2014). In contrast, our experiments demonstrate a strong activation of TMBP-
EM cells in the lung already 24 h p.t. Additionally, transferred T cells can barely be detected in 
the mediastinal lymph nodes before D3 p.i. 
In order to test the capacity of lung-derived antigen-presenting cells (APCs) to activate TMBP-
EM cells, we isolated an APC-enriched cell fraction from naïve lungs (Fig. 15A). We determined 
the immune cell composition of the isolated fraction and observed that most of the isolated 
cells (88 %) were CD11b/c+ CD172a+ myeloid cells. Of this fraction, 21.4 % and 78.6 % exhibited 
a high and low-level expression of MHCII, respectively. The MHCIILO myeloid cells could be 
further sub-categorized in two populations based on their size measured in the forward 
scatter (FSC): 39 % were relatively small whereas the remaining 61 % exhibited a high FSC 
intensity, indicating a large cell size, which in combination with a low expression of MHCII is 
characteristic of alveolar macrophages. As expected, lymphocytes only constituted a minor 
proportion of the labelled cells: 8.4 % and 1.2 % were CD4+ and CD8+ T cells, respectively. B 
cells made up 2.4 % (Fig. 15B).  
Next, we tested the capacity of the isolated lung cell fraction to activate TMBP-EM cells by co-
culturing both cell populations in presence of MBP. Two days after antigen encounter, T cells 
were adoptively transferred into naïve recipient animals (Fig. 15A). All animals developed EAE 
starting on D4 and peaking on D6 p.t. Afterwards, the clinical scores started to decrease and 




Figure 15: TMBP cells stimulated in vitro by lung-derived antigen-presenting cells are encephalitogenic. (A) Experimental 
design: Lung cells enriched for antigen-presenting cells (APCs) were isolated via a 14.5 % Nycodenz gradient. The immune 
cells composition of the isolated fraction was determined by surface marker staining and flow cytometry. Moreover, the 
isolated cells were co-cultured with TMBP-EM-GFP cells and MBP. Two days later, 2.5 x 105 TMBP-blast-GFP cells from culture were 
adoptively transferred into naïve recipient rats. (B) Immune cell composition of the cell fraction isolated from naïve rats. The 
pie chart represents the percentage of stained cells of the corresponding immune cell populations. The following antibody 
combinations were used to differentiate immune cell types (% = percentage of stained cells): CD4+ T cells: CD4+ TCR+ (8.4 
%); CD8+ T cells: CD8a+ TCR+ (1.2 %); B cells: CD45RA+ RT1B+ (2.4 %); myeloid cells in general: CD11b/c+ CD172a+ (88 %); 
MHCIILO FSCLO myeloid cells (27 %); MHCIILO FSCHI myeloid cells: alveolar macrophages (42.2 %); MHCIIHI myeloid cells (18.8 









3.1.2 Examination of the antigen dose-dependent difference in EAE severity 
3.1.2.1 Lung immunization with high antigen doses does not appear to locally trap immune 
cells 
 
While establishing the lung EAE model, we unexpectedly observed that EAE induced by 
immunization with higher doses of antigen (50 µg MBP / 300 g body weight; HI) is less severe 
than when induced using a 50-fold reduced dose (1 µg MBP / 300 g body weight; LO-OPT; Figs. 
7 and 11). We reasoned that a stronger lung inflammation induced by higher doses of antigen 
could potentially trap innate immune cells within the lung, thereby preventing their 
contribution to CNS inflammation. In order to test this hypothesis, rats were adoptively 
transferred with CNS-ignorant TOVA-EM cells and i.tr. immunized with HI or LO-OPT doses of 
OVA antigen to induce local inflammation. Two days later, the animals additionally received 
TMBP-blast cells (Fig. 16A). A control group of animals received TOVA-EM cells and two days later 
TMBP-blast cells without being immunized (NAI; Fig. 16A). 
In both the HI OVA and LO-OPT OVA group, EAE onset was delayed by approximately one day 
compared to the NAI group (Fig 16B, D). Both groups, however, developed EAE of similar 
severity with identical peak scores of 2.83 ± 0.08 (Fig. 16E) and similar cumulative scores (LO-
OPT OVA: 14.08 ± 0.72; HI OVA: 12.92 ± 0.44). The cumulative scores of both groups were 
significantly lower than of the NAI group (21.25 ± 2.55; Fig. 16F). Taken together, these data 
suggest a mild but antigen dose-independent effect of i.tr. immunization on the clinical 
outcome of EAE that obviously cannot justify the observed difference in clinical outcome 
following i.tr. immunization with different doses of MBP. 
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Figure 16: TMBP-blast cell transfer following i.tr. immunization with high or low concentrations of a non-self antigen. (A) 
Experimental design: Rats received 5 x 106 TOVA-EM-Cherry cells i.v. and were i.tr. immunized 6 – 12 h later with a high (50 µg / 
300 g body weight; HI) or low (1 µg / 300 g body weight; LO-OPT) dose of OVA and CFA (10 µg / 300 g body weight). A control 
group received cells but was not immunized (NAI). Two days later, the animals were transferred with 1 x 106 in vitro activated 
TMBP-blast-GFP cells. (B) Body weight change (lines) and clinical scores (bars) over the course of EAE. (C) Incidence (%). (D) Average 
onset (days p.i.). (E) Average peak score. (F) Average cumulative score. Values are represented as mean ± SEM. Statistical 
significance was determined via one-way ANOVA with Tukey´s multiple comparisons test. *p < 0.05. 
 
3.1.2.2 TMBP-EM cells activated in the lung with high antigen concentrations do not appear to 
be anergic or impaired in their proliferation potential 
 
Next, we hypothesized that TMBP-EM cells activated with a high MBP concentration might be 
impaired in their functionality: indeed, strong TCR stimulation can induce T cell exhaustion or 
anergy. To address this hypothesis, rats were i.tr. immunized with the HI or LO-OPT MBP dose 
following TMBP-EM cell transfer. After 7 days, the transferred T cells were isolated from 
peripheral organs and stimulated in vitro (Fig. 17A). T cell activation and proliferation served 
as read-out (Fig. 17B, C).  
Compared to the control conditions (no antigen; -MBP), T cells isolated from both the HI and 
the LO-OPT group strongly increased the expression of IFN and IL-17 mRNA, indicative of an 
48 
ongoing activation. However, no significant differences in cytokine expression could be 
observed between the antigen-stimulated (+MBP) groups. (Fig. 17B).  
A slightly higher expression of the surface activation marker IL-2R (CD25) was observed in T 
cells from the LO-OPT group (Fig. 17C) upon antigen stimulation. However, the expression in 
both the LO-OPT +MBP and the HI +MBP group was highly upregulated compared to the 
corresponding -MBP control groups.  
The proliferation of T cells from both groups was similar on D2 after antigen encounter and 
further increased on D3 and D4 following the addition of IL-2 in both groups.  
Taken together and despite minor differences in activation and proliferation between the 
groups, these data indicate that T cells activated in the lung using high antigen concentrations 
were not impaired in their basic functions.  
 
Figure 17: Proliferation and activation of TMBP cells previously activated in the lung with high or low MBP concentrations. 
(A) Experimental design: Rats received 7.5 x 106 TMBP-EM-GFP cells i.v. and were i.tr. immunized 6 – 12 h later with a high (50 µg 
/ 300 g body weight; HI) or low (1 µg / 300 g body weight; LO-OPT) dose of MBP and CFA (10 µg / 300 g body weight). Five 
days later, the transferred T cells were isolated from blood and mediastinal lymph nodes and stimulated with (+) or without 
(-) MBP and irradiated thymocytes in vitro. T cell activation and proliferation was assessed via qPCR and flow cytometry. (B) 
T cell activation on mRNA level was determined using qPCR based on the expression of IFN and IL-17. Expression (2-ΔCT) was 
normalized to -actin expression of the same samples. (C) T cell activation on protein level was determined using antibody 
labeling and flow cytometry based on the expression of CD25. (D) Changes in T cell numbers on D2, 3 and 4 compared to D0 
were determined using flow cytometry. On D2, IL-2 was added to the cells to boost proliferation. Representative data of two 
independent experiments. 
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3.1.2.3 The antigen dose-dependent difference in EAE severity is T cell-intrinsic and 
transferable  
 
Next, we examined whether the observed difference in EAE severity between the HI and the 
LO-OPT group was T cell-intrinsic. To this end, rats were i.tr. immunized with the HI or LO-OPT 
MBP dose following TMBP-EM cell transfer. After 3.5 days, the spleens were harvested and the 
transferred T cells isolated. Equal numbers of previously transferred TMBP-EM cells isolated from 
the spleens of both donor groups were subsequently re-transferred into naïve recipient 
animals (HI and LO-OPT recipient group). After additional 3.5 days, the re-transferred T cells 
were quantified in different organs of the recipients (Fig. 18A).  
In all peripheral organs examined, the amount of T cells was similar between the groups with 
slight tendencies toward a higher number in the lung of the LO-OPT recipient group and in the 
blood of the HI recipient group (Fig. 18B). In contrast, in the spinal cord, a significant difference 
in T cell numbers could be observed between the groups: an average of 1.13 x 105 T cells / g 
was detected in the LO-OPT recipient group compared to an average of 2.26 x 104 cells / g in 
the spinal cord of the HI recipient group (Fig. 18B). Owing to the generally low yield of re-
transferrable T cells and comparably low number of these cells entering the CNS of the re-
transfer recipient animals, only mild clinical symptoms occurred. Importantly, this was only 
the case in the recipient animals of the T cells isolated from the LO-OPT group. The HI recipient 
group, in contrast, remained symptom-free (data not shown). Consequently, the dose-
dependent difference in EAE severity appears to be T cell-intrinsic. 
 
Figure 18: Re-transfer of TMBP cells from rats i.tr. immunized with high or low MBP concentrations. (A) Experimental design: 
Rats received 7.5 x 106 TMBP-EM-GFP cells i.v. and were i.tr. immunized 6 – 12 h later with a high (50 µg / 300 g body weight; HI) 
or low (1 µg / 300 g body weight; LO-OPT) dose of MBP and CFA (10 µg / 300 g body weight). 3.5 days later, the transferred 
T cells were isolated from the spleens of both groups. 2.5 x 106 isolated T cells were re-transferred into naïve recipient 
animals. Another 3.5 days later, T cell distribution in different organs was determined via flow cytometry. (B) T cells per g or 
mL detected in the indicated organs. Cumulative data from four independent experiments. Values are represented as mean 
± SEM. Statistical significance was determined via two-tailed t-test. *p < 0.05. 
50 
3.1.2.4 Similar ratios of TCR-V-T cell subclones in blood and spinal cord of the HI and the 
LO-OPT group 
 
The TMBP-EM cell lines used in our setup are established in WT Lewis rats and therefore 
polyclonal, meaning that they potentially could express differing T cell receptors (TCRs) with 
distinct capacities to react to MBP epitopes. Consequently, they could exhibit varying 
encephalitogenic potentials. A restricted amount of available antigen could favor the 
activation and expansion of potentially more pathogenic TMBP-EM cell subclones carrying a TCR 
with an optimal affinity / avidity for a specific MBP epitope (Fig. 19A).  
In order to test whether this hypothesis might explain the effect underlying the observed 
antigen dose-dependent difference in EAE severity, rats were i.tr. immunized with the HI or 
LO-OPT MBP dose following TMBP-EM cell transfer. 5 days later, the percentage of different T 
cell subclones in the blood and CNS of the two groups was determined based on their 
expression of the common MBP-specific V-chains 16, 10, 8.5 and 8.2 (Fig. 19B).  
In the blood, the percentage of the different TCR-V-chain+ T cells was not distinguishable 
between the two groups. Indeed, more than 80 % of the labelled T cells in both groups 
expressed the TCR-V-chain variant 8.2, (Fig. 19C, D). 6 – 7 % expressed the TCR-V16 chain 
and 4 – 5 % of the T cells was positively labelled for either TCR-V8.5 or V10 (Fig. 19C).  
In the spinal cord, the expression pattern of the different TCR was similar between the groups 
but the percentage differed slightly: 80 % of the cells in the spinal cord of the HI group 
expressed the TCR-V8.2 chain. In the LO-OPT group, this percentage was decreased to 55 %. 
A significant difference between the groups was observed for the expression of the TCR-V16 
chain: about 18 % of the transferred T cells of the LO-OPT group were positively labelled for 
this variant, compared to 8.6 % in the HI group. A similar trend (17 % compared to 7 %) but 
without reaching statistical significance could be observed for the TCR-V10+ T cells. With 6 
and 10 % of labelled cells, the TCR-V8.5+ T cell ratios were more similar between the HI and 
LO-OPT group, respectively (Fig. 19D). Given that there was no difference detectable in the 
ratio of TCR-V+ T cells in the blood, a selective expansion of a particularly pathogenic TMBP-EM 
cell subclone seems unlikely but cannot be excluded. 
51 
 
Figure 19: Ratio of different TCR-V-T cell subclones in blood and CNS of rats i.tr. immunized with high or low MBP 
concentrations. (A) Hypothesis: The antigen dose-dependent difference in EAE severity could result from a differential TMBP-
EM cell subclone expansion. Low concentrations of MBP might result in the selective expansion of subclones that are more 
pathogenic or more capable of transgressing the BBB. (B) Experimental design: Rats received 7.5 x 106 TMBP-EM-GFP cells i.v. and 
were i.tr. immunized 6 – 12 h later with a high (50 µg / 300 g body weight; HI) or low (1 µg / 300 g body weight; LO-OPT) dose 
of MBP and CFA (10 µg / 300 g body weight). Five days later, the transferred T cells in blood and spinal cord (CNS) were 
antibody-labeled for the expression of different TCR-V chains (V16; V10; V8.5; V8.2) and acquired via flow cytometry. 
(C – D) Percentage of the different antibody-labeled TCR-V-TMBP-GFP cell subclones in the blood (C) and spinal cord (CNS; D). 
Cumulative data from two independent experiments. Values are represented as mean ± SEM. Statistical significance was 











3.1.2.5 The antigen dose-dependent difference in EAE severity still occurs when using a 
monoclonal TMBP-EM cell line 
 
To definitely address whether a selective expansion of a specific TCR subclone could underlay 
the observed difference in EAE severity using LO-OPT or HI antigen doses, we took advantage 
of a monoclonal TMBP-EM cell line established from TCRMBP-transgenic (TG) animals. In these 
animals, about 95 % of TCR+ T cells express the identical TCR-V-chain variant 8.2. Of note, 
this TCRMBP reacts in vitro to antigen doses around 100 times lower than commonly used for 
WT T cells. 
Rats were adoptively transferred with TG TMBP-EM cells and i.tr. immunized with the following 
concentrations of MBP: HI (50 µg MBP), LO-OPT (1 µg MBP), LO-SUB (0.01 µg MBP), as well as 
an extremely low antigen dose (XTR-LO; 0.1 ng MBP; all concentrations per 300 g body 
weight). Animals transferred with TG T cells but not immunized (NAI) or immunized with CFA 
alone (CFA) served as control groups. 
Similar to the WT cell line, TG T cells induced EAE of varying severity dependent on the antigen 
concentration used for their activation. As observed using WT cells, the most severe EAE with 
an incidence of 100 % and a peak score of 2.16 ± 0.32 was induced in the LO-OPT group. The 
HI group only developed a mild EAE with an incidence of 62.5 % and a peak score of 0.78 ± 
0.3. As expected, EAE induced in the LO-SUB group was stronger compared to using WT cells. 
The incidence was 85.7 % and the average peak score was 1.4 ± 0.42 (Fig. 20A – D). Onset in 
all three groups was between D5 and 5.4 p.i. (Fig. 20C). The NAI, CFA and XTR-LO groups 
remained disease-free throughout the course of the experiment. 
In addition to the clinical course, we determined the distribution of TG T cells in different 
organs on D5 p.i., that is, between onset and peak of the disease. With minor exceptions in 
lung and inguinal lymph nodes, the cell numbers were comparable in all peripheral organs 
examined (Fig. 20F – J). In contrast, clear differences in TG T cell numbers between the groups 
were observed in the spinal cord: in line with the clinical course, the by far and significantly 
highest number of TG T cells compared to all other groups (3.73 x 105 / g) was detected in the 
LO-OPT group. In the HI group, TG T cell numbers were about 10x lower (3.33 x 104 / g). In the 
LO-SUB group, 7.9 x 104 TG T cells / g had infiltrated the spinal cord by D5 p.i. The XTR-LO 
group showed low-level TG T cell infiltration of about 2.5 x 104 cells / g. No cells were detected 
in the spinal cord of the CFA and the NAI group (Fig. 20K). 
The fact that the antigen dose-dependent difference in EAE could also be observed when using 
a TCR-transgenic monoclonal TMBP-EM cell line demonstrates that a differential and selective T 
cell subclone expansion when immunizing with low antigen concentrations can be excluded 




Figure 20: Characterization of TCRMBP-transgenic T cell distribution in different organs during i.tr. induced EAE. Rats received 
7.5 x 106 TCRMBP-transgenic (TG) TMBP-EM-GFP cells and were i.tr. immunized 6 – 12 h later with varying doses of MBP (0 µg: NAI 
and CFA; 0.1 ng: XTR-LO; 0.01 µg: LO-SUB; 1 µg: LO-OPT; 50 µg: HI; all per 300 g body weight) and CFA (0 µg: NAI; 10 µg: rest; 
all per 300 g body weight). (A) Body weight change (lines) and clinical scores (bars) over the course of EAE. (B) Incidence (%). 
(C) Average onset (days p.i.). (D) Average peak score. (E) Average cumulative score. (F – K) TG T cells per g or mL detected in 
the indicated organs on D5 p.i. Cumulative data from three (A) or two (B – K) independent experiments. Values are 
represented as mean ± SEM. Statistical significance was determined via one-way ANOVA with Tukey´s multiple comparisons 





3.1.2.6 The expression of adhesion-related genes by TMBP cells activated in the lung may be 
differently regulated by different antigen concentrations 
 
Next, we investigated if TMBP-EM cells activated in the lung with higher antigen concentrations 
might be impaired in their potential to transmigrate through the BBB and enter the CNS. 
To test this hypothesis, we determined the expression of integrins and chemokine-receptors 
known to be relevant for T cell infiltration into the CNS in transferred T cells sorted on D5 p.i. 
(onset of EAE) from the blood of animals immunized with varying MBP concentrations (LO-
SUB, LO-OPT, HI), only CFA (CFA), or not immunized at all (NAI; Figs. 10 – 12).  
VLA-4 expression of T cells from both the HI and LO-OPT group was about twice as high as in 
the NAI group. This increased expression, however, was similar in both groups. No 
upregulation of VLA-4 could be observed in the CFA and the LO-SUB group (Fig. 21A). 
LFA-1 expression of T cells from the blood of the HI group was significantly reduced by almost 
50 % compared to the NAI group. Furthermore, it was significantly lower than in the CFA and 
LO-SUB but not the LO-OPT group (Fig. 21B). No significant difference could be observed 
between the NAI, CFA, LO-SUB and LO-OPT groups. 
The expression of CXCR3 tended to be upregulated in all groups compared to the NAI group. 
The only significant difference, however, was observed between the NAI and LO-OPT group. 
CXCR4 was significantly downregulated in T cells from the blood of the CFA, LO-OPT and HI 
groups compared to the NAI group. The difference between NAI and HI was most pronounced: 
CXCR4 expression in the HI group was decreased by more than 70 % (Fig. 21B). 
Downregulation of CXCR4 expression in the CFA and the LO-OPT group compared to the NAI 
group was about 33 and 40 %, respectively (Fig. 21B).  
No difference in the expression of CCR5 and CCR6 could be observed between the groups (Fig. 
21B).  
Taken together, we could observe some differences between the groups in the expression of 
adhesion-related genes. In case of LFA-1 and CXCR4, the expression was most strongly 
downregulated in the HI group. Whether these effects may be of relevance regarding the 
differences observed in EAE severity remains to be further examined.  
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Figure 21: Antigen dose-dependent integrin- and chemokine-receptor expression of TMBP cells from blood before CNS 
infiltration. Rats received 7.5 x 106 TMBP-EM-GFP cells and were i.tr. immunized 6 – 12 h later with varying doses of MBP (0 µg: 
NAI and CFA; 0.01 µg: LO-SUB; 1 µg: LO-OPT; 50 µg: HI; all per 300 g body weight) and CFA (0 µg: NAI; 10 µg: rest; all per 300 
g body weight). On D5 p.i., the transferred T cells were sorted from the blood and the expression of different integrins and 
chemokine-receptors was determined using qPCR. (A) Relative expression (difference compared to NAI in %) of the integrins 
VLA-4 (left) and LFA-1 (right). (B) Relative expression (difference compared to NAI in %) of the chemokine-receptors CXCR3, 
CXCR4, CCR5, CCR6 (from left to right). Expression of all genes (2-ΔCT) was normalized to -actin expression of the same 
samples. Cumulative data from three independent experiments. N = 3 – 5 / group. Values are represented as mean ± SEM. 
Statistical significance was determined via one-way ANOVA with Tukey´s multiple comparisons test. *p < 0.05; **p < 0.01; 





















3.2. The role of lung and gut microbiota for i.tr. induced EAE 
3.2.1 The lung hosts a complex microbiota distinct from the gut microbiota  
 
First, we aimed to characterize the lung and gut microbiota of the Lewis rats used in our 
experiments. To this end, BAL fluid (BALF) and feces were collected from a group of animals. 
The animals had been i.tr. treated with sterile PBS for 7 days as they served as control group 
for another experimental setup (see 3.2.4). DNA from the samples was purified and analyzed 
via NGS to characterize the bacterial communities. The V3 – V4 16S rRNA region was used to 
determine the operational taxonomic units (OTUs) and exact amplicon sequence variants 
(ASVs). For the BALF samples, a total of 2,062 ASVs were identified from 950,104 reads. In 
comparison, a total of 4,185 ASVs were identified from 742,446 reads in the fecal samples.  
The most dominant phyla found in the BALF samples were Firmicutes (28.3 %), Proteobacteria 
(24.8 %), Bacteroidetes (11.2 %) and Verrucomicrobia (9.4 %). Additionally, Planctomycetes 
(4.4 %) and Actinobacteria (2.5 %) were found to minor extents. 
Most dominant phyla detected in the fecal samples were Bacteroidetes (41.2 %), Firmicutes 
(34.9 %), Verrucomicrobia (8 %) and Cyanobacteria (5.4 %). Additionally, Epsilonbacteria (4.3 
%) and Proteobacteria (3.3 %) were found to minor extents. 
Of note and in contrast to the fecal samples, the BALF microbiota showed a high percentage 
of rare and unclassified taxa (Fig. 22).  
Taken together, the microbiota composition of lung and gut showed marked differences. 
 
 
Figure 22: Comparison between lung and gut microbiota composition. BAL fluid (BALF) and feces from rats previously 
treated i.tr. with PBS for 7 days were collected. DNA from the samples was purified and analyzed via amplicon sequencing of 
the V3 – V4 16S rRNA region to characterize the bacterial communities based on the operational taxonomic units (OTUs) and 
exact amplicon sequence variants (ASVs). The relative abundances of bacterial ASVs (phylum – class – order) with > 1.0 % 
relative abundance per sample are depicted and color-coded. Cumulative data from two independent experiments. BALF: N 
= 8; Feces: N = 6. Data represented as mean. 
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3.2.2 Neomycin does not interfere with T cell pathogenicity 
 
Next, we aimed to modify the composition of the lung microbiota by local administration of 
antibiotics. In order to exclude a systemic effect, the locally acting aminoglycoside neomycin 
was chosen. Neomycin is a broad-spectrum antibiotic that acts excellently against Gram-
negative and partially against Gram-positive bacteria.  
First, we tested whether neomycin was toxic for T cells. To this end, TMBP-EM cells were 
activated in vitro in presence of varying concentrations of neomycin (NEO). T cell proliferation 
was determined on D2, D3 and D4 after antigenic stimulation (Fig. 23B). 
We did not observe an impairment in T cell proliferation at any of the tested concentrations 
ranging from 0 to 10 mg / mL. Only at 100 mg / mL, T cells did not proliferate and the cell 
numbers progressively decreased (Fig. 23B). Of note, neomycin at this very high dose was 
barely soluble and the pH indicator of the medium instantly indicated acidic conditions upon 
antibiotic addition. 
To test whether neomycin may have an effect on T cell pathogenicity in vivo, TMBP-blast cells 
previously stimulated in vitro in presence of neomycin (1 or 10 mg / mL) or PBS were 
adoptively transferred into naïve recipient animals (Fig. 23A). All groups developed a severe 
EAE starting on D5 p.t. and reaching its peak on D7 p.t. before clinical symptoms started 
vanishing again until the animals were disease-free on D11 p.t. (Fig. 23C). There was no 
difference in any of the clinical parameters detectable between any of the tested groups (Fig. 
23D – G). 




Figure 23: Effect of neomycin on TMBP cell proliferation and pathogenicity. (A) Experimental design: TMBP-EM-GFP cells were 
stimulated with irradiated thymocytes and MBP in presence of varying doses of neomycin (NEO). T cell proliferation was 
determined and 2.5 x 105 T cells were adoptively transferred into naïve recipient rats two days post-stimulation (TMBP-blast-GFP 
cells) to test their pathogenicity following exposure to NEO. (B) Quantification of T cells cultured in presence of NEO ranging 
from 0 to 100 mg / mL on D2, 3 and 4 post-stimulation using flow cytometry. (C – G) Clinical outcome of transfer EAE using 
TMBP-blast-GFP cells previously stimulated in presence of 1 or 10 mg / mL or without NEO. (C) Body weight change (lines) and 
clinical scores (bars) over the course of EAE. (D) Incidence (%). (E) Average onset (days p.i.). (F) Average peak score. (G) 
Average cumulative score. Values are represented as mean ± SEM. Statistical significance was determined via one-way 




3.2.3 Daily administration of neomycin only induces lung inflammation at a dose of 5 mg per 
day 
 
Next, we aimed to find a dose of neomycin sufficient to change the composition of the lung 
microbiota without causing lung tissue irritation. To this end, rats were treated daily with 
three different concentrations of neomycin (0.1, 1 or 5 mg) or PBS for 7 days. On D7 of 
treatment, the immune cell composition of the lungs was determined.  
We observed a significant upregulation of CD4+ T cells (Fig. 24A), CD8+ T cells (Fig. 24B) 
neutrophils (Fig. 24D) and CD11b/c+ cells (both MHCIILO and MHCIIHI; Fig. 24E) in the lungs of 
the 5 mg treatment group compared to the other groups, indicative of an ongoing 
inflammation. No difference was observed between the PBS, 0.1 mg and 1 mg neomycin 
groups in any of the immune cell subsets examined (Fig. 24A – E).  
In line with these results, we observed an increase in body weight of about 5 – 10 % in the 
PBS, 0.1 mg and 1 mg neomycin group, compared to only 1 % in the 5 mg group (Fig. 24F). 
 
Figure 24: Quantification of immune cells in the lung following neomycin treatment. Rats were i.tr. treated daily with 
neomycin (NEO; 0.1 mg, 1 mg, 5 mg) or PBS for 7 days. On D7 of treatment, different immune cell populations of the lungs 
(cells / g) were quantified as a measure of inflammation using antibody labeling and flow cytometry. The following antibody 
combinations were used to label the corresponding immune cell types: (A) CD4+ T cells: CD4+ TCR+. (B) CD8+ T cells: CD8a+ 
TCR+. (C) B cells: CD45RA+ RT1B+. (E) myeloid cells: CD11b/c+ MHCIILO (left), CD11b/c+ MHCIIHI (middle) and ratio of MHCIIHI 
/ CD11b/c+ cells (right). (F) Body weight change of the four treatment groups after 7 days of treatment (%). Cumulative data 
from three independent experiments. Values are represented as mean ± SEM. Statistical significance was determined via 
one-way ANOVA with Tukey´s multiple comparisons test. *p < 0.05; **p < 0.01; ***p < 0.001.  
 
3.2.4 Neomycin treatment appears to alter the lung microbiota composition in a dose-
dependent manner 
 
Next, we investigated if neomycin can modify the composition of the lung microbiota. To this 
end, rats were i.tr. treated daily with 0.1, 1 or 5 mg neomycin or PBS (see 3.2.1) for 7 days. On 
D7 of treatment, BAL fluid (BALF) and feces were collected and analyzed via NGS as previously 
described (3.2.1).  
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With increasing neomycin concentration, the composition of the lung microbiota appeared to 
change: the percentage of some of the Bacteroidetes classes of Bacteroidia for example 
appeared to increase whereas some Firmicutes classes as well as some Proteobacteria classes 
of Gammaproteobacteria appeared to decrease (Fig. 25). 
In contrast, i.tr. neomycin treatment did not appear to affect the overall composition of the 
gut microbiota (Fig. 25). 
 
 
Figure 25: Effect of i.tr. neomycin treatment on lung and gut microbiota composition. BAL fluid (BALF) and feces from rats 
previously treated i.tr. with neomycin (NEO; 0.1 mg, 1 mg, 5 mg) or PBS for 7 days were collected. Sample preparation, 
analysis and depiction as in Fig. 22 with the exception that each column represents the microbial composition of one 




We further analyzed the neomycin-induced change of the microbial composition in the lung 
in more detail by focusing on the 15 most abundant taxa on genus level.  
Bacillus (phylum Firmicutes) exhibited a decrease in abundance at all tested concentrations. 
Achromobacter, Rodentibacter and Streptococcus were reduced upon treatment with 1 and 5 
mg of neomycin in a dose dependent manner. The genera Helicobacter, Prosthecobacter and 
Flavobacterium, in contrast, were increased in a dose-dependent manner (Fig. 26A).  
In the gut, only moderate changes were detected: Alistepes and Helicobacter represented the 
most up- and downregulated bacteria, respectively. The changes in abundance were dose-
dependent (Fig. 26A). 
In order to quantify the effect of the antibiotic treatment, we next determined the microbial 
diversity (-diversity) of BALF and feces using four indices: Shannon, Simpson, Invsimpson and 
Chao1. In all cases, a general trend toward an increased -diversity of the BALF microbiota 
induced by i.tr. neomycin treatment could be observed. This increase was in general dose-
dependent and significant in the 1 mg dose for the Simpson index and in the 5 mg dose for 
the Chao1 index. 
No tendency toward an altered -diversity could be observed for the fecal samples. Instead, 
-diversity of the three neomycin groups was very similar to the PBS group (Fig. 26B – E).  
Taken together, neomycin treatment altered the composition of the BALF but not fecal 




Figure 26: Effect of i.tr. neomycin treatment on lung and gut microbiota genera and -diversity. Sample collection, 
preparation and analysis as described in Fig. 22. (A) The heat map represents the average relative fold changes in % read 
abundance of the 15 most abundant genera of BAL fluid (BALF) and feces normalized to the corresponding PBS groups. (B – 
D) Indices (as indicated) for -diversity of the microbiota composition of BALF (upper row) and feces (lower row). Cumulative 
data from two independent experiments. Values are represented as mean ± SEM. Statistical significance was determined via 







3.2.5 Neomycin treatment prevents i.tr. induced EAE 
 
Having observed that intrapulmonary neomycin treatment changes the composition of the 
local microbiota, we wanted to test its potential effect on i.tr. induced EAE. To this end, rats 
were i.tr. treated daily with neomycin (0.1, 1 or 5 mg) or PBS for 7 days. Non-treated animals 
(CTRL) were used as additional control. On D7 of treatment, the animals were immunized with 
the LO-OPT MBP dose following TMBP-EM cell transfer. On D7 p.i., the peak of disease, the 
distribution of the transferred T cells in different organs was determined (Fig. 27A).  
Strikingly, while the animals of the two control groups and the 0.1 mg neomycin group 
developed typical EAE with very similar clinical parameters (incidence: 100 %; average onset: 
D5.7 – D6.5 p.i.; average peak score: 2.1 – 2.2), daily treatment with 1 mg and 5 mg neomycin 
completely prevented EAE (Fig. 27B – E).  
In line with the clinical data, the number of transferred T cells detected in the spinal cord (CNS) 
of the control groups and 0.1 mg neomycin group on D7 p.i. were similar and ranged from 
2.62 x 105 ± 5.67 x 105 / g in the CTRL to 3.16 x 105 ± 5.67 x 105 / g in the PBS group. T cell 
numbers in the CNS of the 1 mg and 5 mg neomycin groups in contrast were 4.7 x 104 ± 2.0 x 
104 / g and 3.1 x 104 ± 1.7 x 104 / g, respectively, and thus significantly lower compared to the 
other three groups (Fig. 27K). There was no significant difference in T cell numbers between 
any of the groups in lung, mediastinal lymph nodes, inguinal lymph nodes, spleen and blood 
(Fig. 27F – J).  
These results clearly demonstrate that intrapulmonary neomycin treatment can efficiently 




Figure 27: Characterization of the effect of i.tr. neomycin treatment on i.tr. induced EAE. (A) Experimental design: Rats were 
i.tr. treated daily with neomycin (NEO; 0.1 mg, 1 mg, 5 mg) or PBS (PBS) for 7 days. One group of animals remained untreated 
(CTRL). On D7 of treatment (D0), the rats received 7.5 x 106 TMBP-EM-GFP cells i.v. and were i.tr. immunized 6 – 12 h later (1 µg 
MBP and 10 µg CFA / 300 g body weight). The rats were continued to be treated daily and the clinical course of EAE was 
monitored for 7 days. On D7 p.i., the distribution of the transferred T cells in different organs was determined using flow 
cytometry. (B) Body weight change (lines) and clinical scores (bars) over the course of EAE. (C) Incidence (%). (D) Average 
onset (days p.i.). (E) Average peak score. (F – K) T cells per g or mL detected in the indicated organs on D7 p.i. Cumulative 
data from two (B – E) or three (F – K) independent experiments. nd = not determined. Values are represented as mean ± SEM. 





3.2.6 Neomycin treatment per os does not appear to affect i.tr. induced EAE 
 
In order to confirm that the observed preventive effect of neomycin on EAE upon i.tr. 
treatment is lung-specific and not gut-dependent, rats were treated with 1 mg neomycin or 
PBS via gavage (per os; p.o.) for 7 days. Because the surface of the gut mucosa is by far larger 
than the lung mucosa, we also included a 10x (10 mg) and 100x (100 mg) higher neomycin 
dose. The rats were i.tr. immunized with the LO-OPT MBP dose following TMBP-EM cell transfer.  
At the peak of EAE, the distribution of the transferred T cells in different organs was 
determined.  
Treatment with 100 mg of neomycin resulted in a decreased survival rate of about 27.6 % by 
D7 of treatment, indicating a toxic effect. The survival rate of the other groups was 100 % (Fig. 
28A). T cell numbers in all the peripheral organs were comparable between all groups and no 
significant differences could be detected (Fig. 28B – F). There was a slight tendency toward a 
reduced number of T cells in the 100 mg neomycin group in mediastinal lymph nodes, spleen 
and blood (Fig. 28C, E, F). In the spinal cord (CNS), a significant reduction of T cells was 
detected only at 100 mg neomycin. No differences could be observed between the PBS, 1 mg 
and 10 mg neomycin groups (Fig. 28G).  
The generally low T cell numbers in different organs of the 100 mg neomycin group as well as 
the decreased survival rate might have resulted from a potential toxic effect of neomycin 
treatment at very high doses.  
In conclusion, the i.tr. dose of neomycin sufficient to prevent T cell infiltration into the CNS 
did not evoke any effect when administered p.o., indicating that a lung-associated mechanism 
could be responsible for the blockage of i.tr. induced EAE. 
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Figure 28: Characterization of the effect of p.o. neomycin treatment on i.tr. induced EAE. Rats were treated p.o. daily with 
neomycin (NEO; 1 mg; 10 mg; 100 mg) or PBS for 7 days. On D7 of treatment (D0), the rats received 7.5 x 106 TMBP-EM-GFP cells 
i.v. and were i.tr. immunized 6 – 12 h later (1 µg MBP and 10 µg CFA / 300 g body weight). The rats were continued to be 
treated daily. On D7 p.i., the distribution of transferred T cells in different organs was determined using flow cytometry. (A) 
Survival (%) over the course of 7 days of NEO treatment (B – G). Transferred T cells per g or mL detected in the indicated 
organs on D7 p.i. Cumulative data from two independent experiments. Values are represented as mean ± SEM. Statistical 
significance was determined via one-way ANOVA with Tukey´s multiple comparisons test. *p < 0.05. 
 
3.2.7 Activation of TMBP-EM cells in the lungs of neomycin-treated rats is not impaired 
 
Next, we investigated whether i.tr. neomycin treatment impairs TMBP-EM cell activation within 
the lung. To this end, rats treated with neomycin or PBS for 7 days were i.tr. immunized with 
the LO-OPT dose of MBP following TMBP-EM cell transfer. Non-immunized animals (NAI) and 
animals immunized with CFA alone (CFA) served as controls. 24 h later, the activation state of 
T cells sorted from the lung was determined. 
Independent of the treatment, the expression of both IFN and IL-17 was highly upregulated 
following i.tr. immunization with the LO-OPT MBP dose. We did not observe any difference 
between neomycin and PBS treatment in any of the immunization or control conditions (Fig 
29A, B).  
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In order to further corroborate these data, we performed transcriptome analysis of the 
transferred T cells sorted from PBS or neomycin-treated animals before and 24 hours after i.tr. 
immunization with the LO-OPT dose of MBP. Principle cluster analysis (PCA) revealed a time 
point-dependent but treatment-independent clustering of T cells sorted from both groups on 
D0 and D1 p.i. with the exception of one outlier in the neomycin group on D0 (Fig. 29C). 
Moreover, normalized counts of IFN and IL-17 expression confirmed an upregulation of the 
expression of both genes on D1 p.i. that was independent of neomycin treatment (Fig. 29D, 
E). We also compared the global expression profile of T cells sorted 24 h p.i. and observed that 
indeed not a single gene was regulated differently between the PBS- and the neomycin-
treated group. 
In summary, these data indicate that the process of intrapulmonary TMBP-EM cell activation was 
not affected by neomycin treatment. 
 
 
Figure 29: Effect of i.tr. neomycin treatment on TMBP-EM cell activation in the lung. Rats were i.tr. treated daily with neomycin 
(NEO; 1 mg) or PBS for 7 days. On D7 of treatment, the rats received 7.5 x 106 TMBP-EM-GFP cells i.v. and were i.tr. immunized 6 
– 12 h later with (MBP; 1 µg MBP and 10 µg CFA / 300 g body weight; A – E) or without (CFA; 0 µg MBP and 10 µg CFA / 300 
g body weight; LO-OPT; A – B) MBP. One group of each treatment was left non-immunized (NAI; A – E). (A – B) 24 h later, 
transferred T cells were sorted from the lungs. T cell activation on mRNA level was determined using qPCR based on the 
expression of IFN (A) and IL-17 (B). Expression of all genes (2-ΔCT) was normalized to -actin expression of the same samples. 
(C – E) 12 h p.t. (D0; non-immunized) or 24 h p.i. (D1; MBP-immunized), transferred T cells were sorted from the lungs of the 
NEO and PBS group and underwent transcriptome analysis using NGS. (C) Principle cluster analysis (PCA) of the expression 
profiles of the sorted T cells. (D – E) Corresponding expression (normalized counts) of IFN (D) and IL-17 (E). Values are 
represented as mean ± SEM. Statistical significance was determined via unpaired two-tailed t-test. 
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3.2.8 Intrapulmonary treatment with neomycin blocks EAE independent of the site of 
immunization 
 
Next, we aimed to investigate whether the preventive effect of i.tr. neomycin treatment on 
EAE is dependent on the site of treatment and / or on the site of immunization. To this end, 
rats were treated with neomycin or PBS administered i.tr. or s.c. for 7 days and subsequently 
i.tr. or s.c. immunized following TMBP-EM cell transfer. In addition to the clinical outcome, 
distribution of the transferred T cells in different organs around EAE onset (D8 p.i.) was 
determined. 
In the animals s.c. treated with neomycin or PBS and i.tr. immunized, no difference in the 
clinical course could be observed between the groups (Fig. 30A, B). All animals developed EAE 
with an average onset around D7 p.i., average peak scores of 1.7 ± 0.09 in the PBS and 1.69 ± 
0.12 in the neomycin group and comparable respective cumulative scores of 3.9 ± 0.32 and 
3.94 ± 0.53 (Fig. 30A, B). Accordingly, no differences in transferred T cell numbers could be 
observed in the spinal cord or any other of the organs examined (Fig. 31A).  
Similarly, the clinical EAE course was almost identical in s.c. immunized animals s.c. treated 
with neomycin or PBS (Fig. 30C, D). All animals developed EAE starting around D9 p.i. The 
average peak score of the PBS group and the neomycin group was about 2.58 ± 0.3 and 2.5 ± 
0.38, respectively (Fig. 30C, D). The respective average cumulative scores were 10.08 ± 1.37 
and 9.92 ± 1.91. In line with the clinical outcome, no significant differences between T cell 
numbers in any of the organs examined could be observed (Fig. 31B). 
In contrast, a strong amelioration of EAE was observed in the animals i.tr. treated with 
neomycin and s.c. immunized (Fig. 30E, F). The incidence of the neomycin-treated group was 
reduced to 75 % compared to 100 % in the PBS group. EAE onset was significantly delayed to 
D11 p.i. compared to D9 p.i. The peak score of the neomycin group was about 0.5 ± 0.2 
compared to about 2.81 ± 0.12 in the PBS group and the cumulative score about 1.13 ± 0.43 
compared to about 11.69 ± 1 (Fig. 30E, F). In line with the clinical data, we observed a 
significantly lower number of T cells in the spinal cords of the neomycin group whereas there 
was no difference in any of the peripheral organs (Fig. 31C). 
In conclusion, the results indicate that intrapulmonary administration of neomycin is crucial 
for the prevention or amelioration of EAE. This effect appears to be at least partially 




Figure 30: Examination of the relevance of treatment and immunization site for the neomycin effect on EAE. Rats were 
treated i.tr. or s.c. daily with neomycin (NEO; 1 mg) or PBS for 7 days. On D7 of treatment, the rats received 7.5 x 106 TMBP-EM-
GFP cells i.v. and were i.tr. (1 µg MBP and 10 µg CFA / 300 g body weight) or s.c. (50 µg MBP and 50 µg CFA / 300 g body weight) 
immunized 6 – 12 h later. The rats were continued to be treated daily via the same route and the clinical course of EAE was 
monitored until the animals had fully recovered. The following combinations of treatment site and immunization site were 
examined: (A – B) S.c. treatment and i.tr. immunization. (C – D) S.c. treatment and s.c. immunization. (E – F) I.tr. treatment 
and s.c. immunization. Graphical depiction of EAE course and clinical parameters arranged from left to right: (A, C, E) body 
weight change (lines) and clinical scores (bars) over the course of EAE; (B, D, F) Incidence (%); Average onset (days p.i.); 
Average peak score. Cumulative data from two independent experiments. Values are represented as mean ± SEM. Statistical 






Figure 31: Examination of the relevance of treatment and immunization site for the neomycin effect on TMBP cell 
distribution. Experimental setup and conditions as in Figure 30. On D7 p.i., the distribution of transferred T cells in different 
organs was determined via flow cytometry. (A) S.c. treatment and i.tr. immunization. (B) S.c. treatment and s.c. immunization. 
(C) I.tr. treatment and s.c. immunization. (A – C) T cells per g or mL detected in the indicated organs on D7 p.i. Values are 

















3.2.9 Intrapulmonary treatment with neomycin ameliorates passive transfer EAE 
 
In order to verify the observation that the protective effect of i.tr. neomycin treatment against 
EAE is independent of the site of induction, we tested the effect of neomycin on ptEAE. 
Therefore, rats were treated with neomycin or PBS for 7 days and subsequently transferred 
with in vitro-activated TMBP-blast cells. I.tr. neomycin administration indeed also ameliorated 
ptEAE (Fig. 32A – E): the incidence of the treated group was reduced to 66.67 % (Fig. 32B). 
Clinical symptoms started on D5.25 ± 0.5 p.t.; a significant delay compared to the onset of the 
PBS group on D4.4 ± 0.25 p.t. (Fig. 32C). Average peak and cumulative scores of the neomycin 
group were 0.67 ± 0.25 and 1.8 ± 0.75, respectively, and thus significantly reduced compared 
to the corresponding scores of 2.25 ± 0.38 and 7.3 ± 1.18 of the PBS group (Fig. 32D, E).  
These results further strengthen our observation that the neomycin effect on EAE is not due 
to an impairment in TMBP-EM cell activation. 
 
Figure 32: Passive transfer EAE in neomycin-treated rats. Rats were i.tr. treated daily with 1 mg neomycin (NEO) or PBS for 
7 days. On D7, the animals received 2.5 x 105 TMBP-blast-GFP cells i.v. The rats were continued to be treated daily. (A) Body weight 
change (lines) and clinical scores (bars) over the course of EAE. (B) Incidence (%). (C) Average onset (days p.t.). (D) Average 
peak score. (E) Average cumulative score. Values are represented as mean ± SEM. Statistical significance was determined via 






3.2.10 Neomycin treatment does not affect blood-brain barrier integrity and endothelial 
expression of adhesion molecules 
 
A recent study found that the gut microbiota contributes to the regulation of BBB permeability 
(Braniste et al., 2014). In order to test a similar function of the lung microbiota, rats were 
treated daily with neomycin or PBS for 7 days. Endothelial cells were sorted from meninges 
and spinal cord parenchyma and the expression of tight junction molecules (claudin-5 and 
occludin) and adhesion molecules (VCAM-1 and ICAM) was determined.  
The expression of all genes examined was similar in the neomycin and the PBS group (Fig. 33A, 
B).  
The data show that neomycin does not influence the expression of genes relevant for BBB 
permeability or T cell diapedesis in meningeal and parenchymal endothelial cells of the spinal 
cord. 
 
Figure 33: Effect of i.tr. neomycin treatment on BBB integrity and expression of adhesion molecules. Rats were i.tr. treated 
daily with neomycin (NEO; 1 mg) or PBS for 7 days. On D7 of treatment, endothelial cells were sorted from spinal cord 
parenchyma and meninges. Expression of the tight junction genes claudin-5 and occludin as well as the adhesion molecule 
genes VCAM-1 and ICAM on mRNA level was determined using qPCR. (A) Gene expression in parenchymal endothelial cells. 
(B) Gene expression in meningeal endothelial cells. Expression of all genes (2-ΔCT) was normalized to -actin expression of the 
same samples. Cumulative data from two independent experiments. Values are represented as mean ± SEM. Statistical 














3.2.11 Neomycin treatment may affect microglia function 
 
The gut microbiota might influence the maturation and function of CNS-resident microglia 
(Erny et al., 2015). We therefore investigated whether the antibiotic treatment of the lung 
microbiota might be associated with functional impairments of microglia. We did not observe 
any differences in the expression of TNF, IL-6 and IL-12 between the neomycin and the PBS 
group following 7 days of treatment (Fig. 34A – C). However, MHCII expression of the 
neomycin group was 30.7 % lower compared to the PBS group (Fig. 34D) suggesting that 




Figure 34: Effect of i.tr. neomycin treatment on microglia-typical gene expression. Rats were i.tr. treated daily with 
neomycin (NEO; 1 mg) or PBS for 7 days. On D7 of treatment, the spinal cord parenchyma was isolated and total tissue gene 
expression of the microglia-typical genes (A) TNF, (B) IL-6, (C) IL-12 and (D) MHCII on mRNA level was determined using 
qPCR. Expression of all genes (2-ΔCT) was normalized to -actin expression of the same samples. Cumulative data from two 
independent experiments. Values are represented as mean ± SEM. Statistical significance was determined via unpaired two-






















4.1 Establishment and characterization of an i.tr. induced EAE model 
 
The role of the lung as an organ potentially crucial for the initiation of autoimmune diseases 
has historically not been thoroughly investigated. In a recent study, however, it was observed 
that adoptively transferred MBP-reactive T cells undergo a functional reprogramming within 
the lung, thereby equipping the cells with the potential to enter the CNS and induce EAE 
(Odoardi et al., 2012). Furthermore, the authors could show that neonatally transferred MBP-
reactive memory T cells that persist in primary lymphatic but also peripheral organs like the 
lung of the recipients throughout adulthood could be activated by intrapulmonary 
administration of MBP and CFA to induce EAE (Kawakami et al., 2005; Odoardi et al., 2012). 
Based on these findings and in order to better understand the role of the lung in the initiation 
of CNS autoimmune disease, we established a lung EAE model induced by activation of TMBP-
EM cells via intrapulmonary immunization. Owing to their retroviral expression of fluorescent 
markers, the model allows us to track and functionally characterize the disease-causing T cells, 
both in the lung and on their way into the CNS. 
T cell activation via the lung has classically been proposed to take place in the lung-draining 
mediastinal lymph nodes: according to this view, antigens expressed by lung pathogens or 
entering the pulmonary system via inhalation are endocytosed by dendritic cells and 
transported to the mediastinal lymph nodes where they are presented to T cells in the context 
of MHCII (Sheridan and Lefrançois, 2011; Caucheteux et al., 2013; Lambrecht et al., 2014). 
Several studies, however, also report that T cell activation can already take place within the 
lung. For instance, it was found that CCR7-/- mice exhibit ectopic proliferation of M. 
tuberculosis-specific CD4+ T cells following infection, even though dendritic cell trafficking 
from lung to mediastinal lymph nodes is defective in these animals (Olmos et al., 2010). 
Moreover, influenza-specific memory CD4+ T cells were found to become reactivated in the 
lung airways within 24 h following secondary challenge (Chapman et al., 2011).  
In our lung EAE model, TMBP-EM cell activation appears to take place in the lung rather than in 
the lung-draining lymph nodes. Several lines of evidence support this proposition: (1) EAE can 
be induced by adoptive transfer of TMBP-EM cells stimulated in vitro with APCs isolated from the 
lung. (2) In vivo i.tr. immunization with LO-OPT or HI antigen concentrations induced TMBP-EM 
cell activation as measured by the strong up-regulation of IFN and IL-17 24 h p.i. in a dose-
dependent manner within the lung. (3) Almost no transferred T cells could be detected or 
retrieved from mediastinal LNs or other peripheral organs at this early time point. (4) 
Transcriptome analysis performed on transferred T cells isolated from the lung 24 h p.i. 
showed a clear shift of the gene expression profile toward proliferation and IFN signaling. 
Therefore, at least the initial steps of T cell activation seem to take place within the lung tissue. 
 
Surprisingly when establishing the i.tr. induced EAE model, we observed that antigen doses 
75 – 150-fold reduced compared to concentrations used for s.c. immunization induced a 
severe EAE. Mild EAE could still be induced at a 750 – 1500-fold reduced dose. This dose could 
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be even further reduced by an additional factor of 10 when using TCRMBP-transgenic TMBP-EM 
cells.  
In the newly established lung EAE model, the number or transferred T cells is relatively high 
and the interval between transfer and immunization relatively short. As a proof of concept 
and to rule out a model-dependent artifact effect, we i.tr. immunized a group of memory rats. 
Similar to the acute model of i.tr. induced EAE, the memory rats developed a severe EAE 
following i.tr. immunization with very low doses of MBP. Together, these observations 
demonstrate that the lung is not just capable of but also extremely efficient in inducing CNS 
autoimmunity. 
This observation might also be of relevance in context of CNS autoimmunity in humans: lung 
infections were found to be correlated with an increased MS risk and are often closely 
followed by disease relapses (Sibley et al., 1985; Buljevac et al., 2002; Oikonen et al., 2011; 
Halenius and Hengel, 2014). While a direct associative link remains elusive, molecular mimicry 
has been suggested as a potential mechanistic basis (Lang et al., 2002; Wucherpfennig and 
Strominger, 1995). According to this theory, epitopes expressed by lung pathogens and 
presented to T cells by APCs could structurally resemble self-antigens and consequently result 
in the activation, proliferation and CNS infiltration of normally dormant autoreactive T cells. 
It is probable that the amount of such pathogen-derived antigens resembling self-structures 
present in the lung during infection is quite low. Our observation that highly reduced antigen 
doses are sufficient and even advantageous over higher doses for TMBP-EM cell activation and 
subsequent EAE induction further underpins the hypothesis that T cell cross-reactivity with 
pathogenic antigens may have mechanistic implications in the development and progression 
of MS.  
Additional research, however, would be required in order to further investigate this 
hypothesis. Examining pathogenicity and functional properties of adoptively transferred TMBP-
EM cells activated by i.tr. immunization with proteins or peptides resembling MBP to varying 
degrees and potentially being derived from pathogens may help to better understand the role 
of molecular mimicry in context of CNS autoimmunity.  
Moreover, the identification of niches and lung compartments as well as APC populations 
important for TMBP-EM cell activation my help shed light on the exact processes that make the 
lung so particularly efficient in context of EAE initiation. 
While titrating the antigen in order to establish the lung EAE model, we observed that high 
antigen doses (HI) as commonly used for s.c. immunizations were not conducive and even 
hindering for EAE development: both number and activation of the transferred T cells 
infiltrating the CNS were highly reduced compared to the LO-OPT group which was in line with 
a strongly ameliorated disease severity. This observation was unexpected and we next aimed 
to narrow down a potential underlying mechanism.  
TMBP-EM cell activation and proliferation in the lung following i.tr. immunization was most 
pronounced in animals receiving the HI concentration of MBP. An enhanced T cell immune 
response may result in a stronger inflammation of the lung, which may in turn result in the 
local sequestering and consequent failed recruitment of innate immune cells (e.g. 
macrophages and neutrophils) to the CNS. This, however, did not appear to be the case: we 
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transferred TOVA-EM cells and i.tr. immunized the animals with HI or LO-OPT concentrations of 
OVA, thus creating a similar inflammatory milieu in the lung as induced by TMBP-EM cell transfer 
and immunization with HI and LO-OPT doses of MBP. We observed that animals of both groups 
developed EAE of similar severity following the transfer of TMBP-blast cells two days later, thus 
indirectly excluding an inflammatory state-dependent trapping of myeloid cells in the lung or 
an impairment in their recruitment to the CNS. In order to further corroborate this 
observation, however, a quantification of different immune cell populations in lung, blood and 
CNS over the entire experimental course would need to be conducted.  
To test whether the mechanism underlying the observed difference in EAE severity could be 
ascribed to T cells, transferred TMBP-EM cells that had been activated in the lung by i.tr. 
immunization with HI or LO-OPT antigen concentrations were isolated from the spleens of 
donor animals and retransferred into naïve recipient animals. The antigen dose-dependent 
difference in i.tr. induced EAE severity could indeed be transferred along with the T cells. Thus, 
the underlying mechanism is most likely T cell-instrinsic.  
An obvious explanation for the antigen dose-dependent difference in i.tr. induced EAE severity 
would be that TMBP-EM cells exposed to higher antigen doses become anergic; a hyporesponsive 
state characterized by a generalized inhibition of proliferation and effector functions. Anergy 
can broadly be subdivided into two different categories, namely (1) clonal anergy, which 
describes a growth cycle arrest following weak or incomplete T cell activation and (2) adaptive 
tolerance, which describes a process of T cell desensitization for their cognate antigen in a 
situation of persistent antigen abundance following initial activation and proliferation. It often 
occurs in environments high in co-inhibitory or low in co-stimulatory signals (Schwartz, 2003; 
Chiodetti et al., 2006; Zheng et al., 2008). A strong activation of TMBP-EM cells in a context of 
inflammation and antigen persistence may also result in T cell exhaustion, a process 
characterized by the stepwise loss of effector functions, which can ultimately result in clonal 
deletion (Han et al., 2010; Yi et al., 2010; Wherry, 2011). In case of both anergy and exhaustion 
we would have expected the TMBP cells previously activated in the lung with high 
concentrations of MBP to be impaired in their activation and / or proliferation potential. This 
was, however, not the case: TMBP cells isolated from the periphery on D5 p.i. could be activated 
and proliferated to a similar degree; independent of the antigen dose used for the prior 
intratracheal immunization. Basic effector functions thus did not appear to be impaired.  
It has been reported that T cell clones with higher affinity receptors can be preferentially 
amplified in conditions of low antigen availability (Rees et al., 1999). Moreover, in an adjuvant-
based vaccination study it was observed that low antigen concentrations result in the selective 
induction of CD4+ T cells with an enhanced functional avidity (Billeskov et al., 2017). We 
hypothesized that a restricted availability of antigen in the lung might result in the selective 
expansion of a small subset of particularly encephalitogenic TMBP-EM cell clones whereas higher 
doses of antigen would result in a broader, non-selective expansion of several clones with 
varying encephalitogenic potential. 
However, TCR reactivities as measured by the ratio of TCR-V chains of previously transferred 
T cells in the blood of animals i.tr. immunized with HI and LO-OPT antigen doses were identical. 
Furthermore, the antigen dose-dependent difference in i.tr. induced EAE severity could also 
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be observed when transferring monoclonal TCRMBP-transgenic T cells, thereby ruling out a 
selective TMBP cell subset expansion as a potential mechanism. 
It has been shown that adoptively transferred TMBP-blast cells must undergo a complex 
reprogramming in peripheral organs in order to gain a migratory profile licensing them to gain 
access to the CNS and induce EAE (Odoardi et al., 2012). In this newly established lung EAE 
model, transferred TMBP-EM cells undergo similar reprogramming following immunization: 
antigen-specific T cells in the blood had not only switched off the activation and proliferation 
program previously induced in the lung by antigenic stimulation, but also additionally acquired 
a new transcriptional profile characterized by an independent and exclusive regulation of 
2579 genes. Based on this observation, we hypothesized that the antigen dose might crucially 
influence these transcriptional changes. As a consequence, TMBP-EM cells activated in the lung 
with HI MBP concentrations could be impaired in their capacity to transgress the blood brain 
barrier. We thus examined their expression of integrins and chemokine receptors described 
to be relevant for transendothelial migration.  
The integrins VLA-4 and LFA-1 are expressed by a variety of leukocytes and participate in the 
establishment of cell-cell interactions preceding diapedesis. Both integrins were described to 
be involved in autoreactive T cell transendothelial migration into the CNS in context of CNS 
autoimmunity (Bö et al., 1996; Dugger et al., 2009; Elovaara et al., 2000; Sheremata et al., 
2005). In the lung EAE model, we observed an upregulation of VLA-4 expression in transferred 
T cells sorted from the blood of the HI and the LO-OPT group before CNS infiltration. This 
upregulation was, however, of similar extent in both groups. On the contrary, LFA-1 
expression was downregulated following i.tr. immunization in the HI group compared to the 
NAI control and also tended to be reduced in the LO-OPT group. In the rat TMBP-blast transfer 
model commonly used in our lab, interference with VLA-4 signaling was shown to block T cell 
transgression of the BBB and ameliorate EAE whereas the interference with LFA-1 alone did 
not affect CNS infiltration or EAE (Bartholomäus et al., 2009). Since the upregulation of VLA-4 
expression was similar in the HI and the LO-OPT group and the expression of LFA-1 if anything 
downregulated in both groups, we concluded that a differential expression of these integrins 
can be excluded as a potential mechanism underlying the antigen dose-dependent difference 
in EAE severity.  
Chemokine-signaling induces directed migration and can activate integrin-mediated adhesion 
of immune cells (Laudanna et al., 2002; Ono et al., 2003): the expression of CXCR3, CXCR4 and 
CCR5 is upregulated in TMBP cells before CNS infiltration (Odoardi et al., 2012; Schläger et al., 
2016). CCR6 signaling was described to be required for Th17 cell infiltration into the CNS via 
the choroid plexus (Reboldi et al., 2009), a process irrelevant in the rat ptEAE model in which 
TMBP cells infiltrate the CNS via the leptomeninges (Schläger et al., 2016). Moreover, signaling 
via CCR5 and CXCR3 determines T cell invasiveness into the CNS by enforcing the adhesiveness 
of TMBP cells to the leptomeninges. In contrast, CXCR4 signaling in this context appears to be 
negligible (Schläger et al., 2016). 
In the lung EAE model, we observed an increased expression of CXCR3 in all groups compared 
to the NAI animals by trend. This increase reached significance in the LO-OPT group but was 
of similar extent in the other groups. No difference in CCR5 and CCR6 expression between the 
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groups could be detected. CXCR4 expression was strongly downregulated in the HI group. 
Reduced expression, however, was also observed in the LO-OPT and the CFA group, though 
less pronounced.  
Since CCR5 and CCR6 expression was not changed and the regulation of CXCR3 and CXCR4 
expression tended to be similar in the LO-OPT and the HI group, a differential expression of 
any of the examined chemokine receptors is unlikely to be causative for the observed effect. 
Taken together, we did not identify a clear mechanism responsible for the antigen dose-
dependent difference in EAE severity. It is not unlikely that the mechanism underlying the 
impaired T cell functionality is multifactorial and owing to a cumulative effect caused by mild 
differences in the expression of several genes. An in-depth transcriptome analysis of 
transferred T cells sorted from the blood of the HI and the LO-OPT group around the time 
point of CNS invasion may help elucidating if the fundamental and global reprogramming of 
TMBP cells residing in the lung is dysregulated or imbalanced following intrapulmonary 
activation with a high antigen dose. In addition, identifying and isolating lung and lymph node 
APCs responsible for the activation of TMBP-EM cells in vivo may help establish an in vitro system 
to functionally compare the relationship between TMBP-EM cells, APCs, microenvironment and 
antigen dose. 
 
4.2 Effect of intrapulmonary antibiotic treatment on EAE 
 
The composition of the gut commensal flora appears to be crucially involved in the regulation 
of the development of autoimmune diseases (Jangi et al., 2016; Ochoa-Repáraz et al., 2009). 
Microbiota disruption using antibiotics or raising mice in sterile conditions strongly 
ameliorates or completely blocks EAE, respectively (Berer et al., 2011; Ochoa-Repáraz et al., 
2009). Recently, also the lung was identified to harbor a unique microbiome (Dickson et al., 
2013, 2014, 2015). Using our lung EAE model, we aimed to investigate a potential functional 
connection between the microbiota and CNS autoimmune responses. Therefore, we first 
determined the natural microbiota composition of lung and gut of Lewis rats, the commonly 
used experimental animal in our lab, and subsequently manipulated it using antibiotics to 
evaluate its role in EAE.  
In line with previous studies (Dickson et al., 2013, 2014, 2015), we confirmed that the lungs 
are colonized by a unique microbiota distinct from the gut in quantity and quality: Indeed, the 
ratio between the gram-negative Bacteriodetes and gram-positive Firmicutes, the most 
abundant phyla detected in both BALF and feces was significantly different. Moreover, gut 
and lung also showed fundamental differences in their microbial composition: For instance, 
the representation of Proteobacteria was much higher in the lung compared to the gut. Fecal 
samples in contrast showed a higher representation of Cyanobacteria. 
We aimed to evaluate the role of the lung microbiota in context of EAE. A combination of the 
broad-spectrum antibiotics neomycin, vancomycin, ampicillin and metronidazole is commonly 
used to deplete the gut microbiota in EAE studies (Ochoa-Repáraz et al., 2009; 2010). The 
latter two antibiotics act systemically and all four are usually administered in relatively high 
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doses. This approach results in a drastic and global depletion of the collective microbiota. As 
alternative approach, EAE studies are often performed in mice raised in germ-free conditions. 
In these animals, however, the lack of a microbiota leads to several defects in anatomical 
immune-related structures and impairs the immune response (Luczynski et al., 2016), 
demonstrating the crucial link between microbiota and the development and function of the 
immune system (Belkaid and Hand, 2014). 
In order to specifically interfere with the lung microbiota without altering the gut microbiota 
and without systemically affecting the immune system, we decided to treat the animals with 
a single and locally acting antibiotic. We chose neomycin, a topical broad-spectrum 
aminoglycoside that mainly but not exclusively targets gram-negative bacteria. 
Daily i.tr. neomycin administration of 0.1 mg, 1 mg and 5 mg for 7 days resulted in changes of 
the microbiota composition and an increase in -diversity in lung but not gut in a dose-
dependent manner. Given the relatively low antibiotic dose administered and the incomplete 
coverage of the neomycin-targeted bacterial spectrum, it is not surprising that the local 
bacterial community was altered rather than depleted and that -diversity was increased 
rather than decreased, as rare taxa not affected by antibiotic treatment may increase in 
abundance and colonize freed up niches in an opportunistic fashion (Price et al., 2017; Lee et 
al., 2018). Whether i.tr. neomycin administration actually affects the bacterial load of the lung 
commensal flora remains to be determined based on the expression of tuf genes using qPCR.  
 
We next investigated the effect of i.tr. neomycin treatment on i.tr. induced EAE and observed 
that T cell infiltration into the CNS and clinical disease were prevented at doses of 1 mg and 5 
mg. Protection from EAE was not the consequence of a direct toxic effect of neomycin on T 
cells nor on their encephalitogenic potential. Moreover, neomycin treatment did not cause a 
strong lung inflammation that might potentially interfere with the initiation of the CNS 
autoimmune response: Indeed at 1 mg / day, the minimum effective dose, the immune cell 
composition of the lung was unaltered compared to PBS-treated control animals. More 
importantly, the preventive effect of neomycin on EAE was not ascribable to a gut-related 
effect: -diversity of the gut microbiota was unchanged following i.tr. treatment with 
neomycin. Moreover, no effects on EAE were observed in animals treated per os with 1 mg or 
10 mg of neomycin daily. These data are not in conflict with previous results demonstrating 
EAE prevention following gut microbiota depletion: Indeed, the protective effect of oral 
antibiotic treatment against EAE required a combination of several antibiotics administered 
at doses higher than in our experimental setup (Berer et al., 2011; Ochoa-Repáraz et al., 2009). 
More importantly, these data strongly support a direct role of the lung microbiota in context 
of EAE. Recolonization of the lungs of neomycin-treated animals with taxa reduced in 
abundance upon antibiotic treatment may help understand whether a single or a combination 
of different taxa could be responsible for the regulation of i.tr. induced EAE.  
Over the past few years, the role of symbiotic interactions between microbiota and local 
environment for the induction, training, and function of the immune system was extensively 
investigated (Belkaid and Hand, 2014). In the gut, the composition of the local community is 
crucially involved in the shaping of CD4+ T cell responses. While certain bacteria trigger pro-
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inflammatory responses (Lee et al., 2011; Scher et al., 2013; Wu et al., 2010), others favor the 
generation of regulatory T cells which in turn participate in the maintenance of gut 
homeostasis (Coombes et al., 2007; Mucida et al., 2005; Sun et al., 2007). Based on these 
findings, we asked ourselves whether the neomycin-induced changes in the lung microbiota 
could affect the nature of the immune response of TMBP-EM cells following their activation. This, 
however, was not the case: The pro-inflammatory profile of the transferred T cells in the lung 
24 h p.i. was similar between the neomycin- and the PBS-treated group. Moreover, 
transciptome analysis of the T cells retrieved from the lungs of both groups 24 h p.i. revealed 
identical gene expression profiles.  
We hypothesized that the observed antibiotic-induced effect on EAE might be independent of 
intrapulmonary T cell activation. Indeed, i.tr. neomycin treatment ameliorated both active 
EAE induced by s.c. immunization and passive transfer EAE induced by in vitro activated TMBP-
blast cells. Independent of the site of immunization, no effect on EAE was observed when the 
antibiotic was s.c. administered.  
While the protective effect of neomycin treatment against EAE appeared to be lung-specific, 
an altered immune response or impaired T cell activation were widely ruled out as underlying 
mechanisms, raising the possibility that the lung microbiota may regulate functional crosstalk 
between lung and CNS through remote control mechanisms. 
Recently, it was shown that the gut microbiota influences BBB permeability, supposedly 
through the release of metabolites like short chain fatty acids (SCFA) into the circulation. An 
increased BBB permeability was observed in mice raised in germ-free conditions; an effect 
that could be reversed by fecal transfer from specific-pathogen-free mice (Braniste et al., 
2014). To test whether i.tr. neomycin treatment affects BBB properties, we sorted meningeal 
endothelial cells and determined the expression of the tight junction genes occludin and 
claudin-5, as well as the adhesion molecules VCAM-1 and ICAM which are the ligands for the 
integrins VLA-4 and LFA-1, respectively. None of these transcripts was expressed differently 
between the groups, thus excluding BBB density dysregulation following i.tr. neomycin 
treatment as a potential mechanism. 
The gut commensal flora also appears to be associated with the regulation of microglia: 
Raising mice in germ-free conditions or depleting their gut microbiota using antibiotics impairs 
microglia maturation, differentiation and function (Erny et al., 2015). Microglia isolated from 
the corresponding animals showed impaired effector functions as indicated by a reduced 
expression of genes including TNF, IL-6 and IL-12 in response to lipopolysaccharide (LPS) 
treatment (Erny et al., 2015). Moreover, microglia have been described to represent the main 
APC population within the CNS parenchyma during neurodegeneration (Schetters et al., 
2018). In order to address a potential functional impairment of microglia following i.tr. 
neomycin treatment, we determined the total tissue expression of the above genes, as well 
as MHCII, in CNS parenchyma isolated from neomycin-treated and non-treated animals. While 
neither TNF nor IL-6 or IL-12 expression was altered, we observed a lower expression of 
MHCII in the neomycin group. How this observation translates into a functional impairment in 
the antigen presentation capacity of microglia or other APCs of the CNS and how this effect is 
mediated, however, remains to be determined. 
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Taken together, these data strongly support the existence of a lung-CNS axis that can influence 
CNS autoimmunity independent of the gut-CNS axis. Further research is required in order to 
understand the mechanistic aspects and identify cellular and metabolic players involved in 
and required for the mutually regulatory interconnection between lung, microbiota and CNS 
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